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Abstract: Pregnancy outcomes in patients with pulmonary hypertension remain poor despite advanced therapies. Although consensus
guidelines recommend against pregnancy in pulmonary hypertension, it may nonetheless occasionally occur. This guideline document
sought to discuss the state of knowledge of pregnancy effects on pulmonary vascular disease and to deﬁne usual practice in avoidance of
pregnancy and pregnancy management. This guideline is based on systematic review of peer-reviewed, published literature identiﬁed with
MEDLINE. The strength of the literature was graded, and when it was inadequate to support high-level recommendations, consensus-
based recommendations were formed according to prespeciﬁed criteria. There was no literature that met standards for high-level recom-
mendations for pregnancy management in pulmonary hypertension. We drafted 38 consensus-based recommendations on pregnancy
avoidance and management. Further, we identiﬁed the current state of knowledge on the effects of sex hormones during pregnancy on the
pulmonary vasculature and right heart and suggested areas for future study. There is currently limited evidence-based knowledge about
both the basic molecular effects of sex hormones and pregnancy on the pulmonary vasculature and the best practices in contraception and
pregnancy management in pulmonary hypertension. We have drafted 38 consensus-based recommendations to guide clinicians in these
challenging topics, but further research is needed in this area to deﬁne best practices and improve patient outcomes.
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SUMMARY OF RECOMMENDATIONS
From “Basic biology of PH and pregnancy”
1. When counseling pregnant women or women considering
pregnancy, healthcare practitioners should inform them regarding
the risks, including possibly persistent pulmonary hypertension of
the newborn (PPHN), and potential beneﬁts of selective serotonin-
reuptake inhibitors (consensus based [CB]).
From “Clinical research on pregnancy outcomes in PH”
1. Although recent studies suggest improved outcomes in the mod-
ern era, maternal morbidity and mortality clearly remain high (CB).
2. In general, patients with pulmonary hypertension (PH), par-
ticularly pulmonary arterial hypertension (PAH), should be coun-
seled to avoid pregnancy (CB).
3. Given the high mortality rate, rapidly evolving treatment
practices, and the need to make complex decisions, early referral
to an experienced PH center, ideally one with experience in the
management of PAH in pregnancy, is an essential part of care of
the pregnant patient with PAH (CB).
From “Prepregnancy counseling and contraception”
1. All patients should be counseled to avoid pregnancy, with a
thorough explanation of risks to both mother and fetus (CB).
2. Permanent contraception should be strongly considered in
PAH patients, with recognition that the ﬁeld of PAH therapy is
advancing and that future outcomes may be improved. Therefore,
we recognize that permanent contraception is neither available to
all patients nor acceptable to all patients (CB).
3. Of permanent contraception methods, hysteroscopic sterili-
zation is preferred because of the potential for lower procedural
risks (CB).
4. If tubal ligation is planned, a laparoscopic approach is rela-
tively contraindicated because of procedural risks. A minilaparotomy
may be a safer method but still requires general anesthesia (CB).
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5. Estrogen-containing contraception is not recommended be-
cause of the increased risk of venous thromboembolic disease
(VTE) and the possible deleterious effects of estrogen on the pul-
monary vasculature (CB).
6. Progestin-only pills may be used, but often a second method is
required because of the relatively high “typical-use” failure rate (CB).
7. Progestin-only intrauterine devices (IUDs) and implants are
acceptable nonpermanent contraception (CB).
8. Injected progestins (depo-provera) are relatively contrain-
dicated because of a likely increased risk of thrombotic events
(although risk is likely to be mitigated if anticoagulants are used
in this population). However, this method may be appropriate in
patients without a history of VTE, because of its superior efﬁcacy
to oral progestin-only pills, when the other, more effective meth-
ods listed above are not available (CB).
9. Barrier and fertility awareness–based methods are not
recommended to prevent pregnancy in PH (CB).
10. Centers managing patients with PH should have access to
family-planning services able to give specialist advice (CB).
From “Genetic counseling in PH”
1. Genetic counseling should be offered to patients with idio-
pathic PAH or heritable PAH (CB).
2. Genetic testing should not be performed in the absence of
genetic counseling (CB).
3. As genetic mutations underlying World Health Organization
(WHO) groups 2, 3, 4, and 5 PH and PAH not due to idiopathic
or heritable disease have not been described, genetic testing and/
or counseling is not required at present for these conditions (CB).
From “Pregnancy management”
1. Pregnancy in PAH patients is associated with a high maternal
mortality rate. The highest-risk periods are the peripartum period
and the immediate postpartum period (up to 2 months) (CB).
2. A multidisciplinary approach with high-risk obstetricians,
PH physicians, cardiologists, anesthesiologists, and neonatologists
is recommended (CB).
3. Close clinical monitoring, including monthly follow-up visits
in the ﬁrst and second trimesters and weekly clinic visits in the
third trimester, is recommended (CB).
4. All pregnant PH patients should be offered pregnancy termi-
nation. In particular, patients with worsening right heart failure,
especially early in their pregnancy, and patients with other high-
risk features should be given the option to have their pregnancy
terminated. If patients want to continue pregnancy, augmentation
of PAH therapy should be considered to improve the chances of a
favorable outcome (CB).
5. Cesarean section is the preferred mode of delivery and should
be used unless not available or in cases of emergencies (CB).
6. Epidural or spinal-epidural anesthesia is recommended rather
than general anesthesia (CB).
7. Because of the potential for catastrophic consequences, preg-
nant PH patients and their providers should be counseled on
inducers and symptoms of vasovagal syncope. Triggers of vasova-
gal syncope should be avoided (CB).
From “Role for PAH-directed therapy
in pregnancy and delivery”
1. In patients who are in WHO functional class (FC) IV or have
evidence of severe right ventricular (RV) impairment, parenteral
prostaglandins are recommended. Most published experience in paren-
teral prostaglandins is with intravenous (iv) epoprostenol (CB).
2. In select patients with more preserved RV function who are
in WHO FC III, inhaled prostaglandins may be considered. Most
published experience in inhaled prostaglandins is with iloprost.
An appropriate treatment response needs to be veriﬁed (CB).
3. Oral phosphodiesterase 5 inhibitors may be considered in
patients who are in WHO FC I or II and who have normal RV
function. Most published experience is with sildenaﬁl. Close follow-
up for deterioration is highly recommended for patients treated
with phosphodiesterase 5 inhibitor monotherapy (CB).
4. Parenteral prostaglandins can be combined with oral phos-
phodiesterase inhibitors in pregnancy. Successful outcomes have
been reported with this regimen (CB).
5. For patients meeting strict criteria for vasodilator-responsive
PAH who are not in WHO FC IV and who do not have RV
dysfunction, calcium channel blocker therapy may be continued
in pregnancy, with close follow-up for deterioration (CB).
6. The currently available endothelin receptor blockers and sol-
uble guanylate cyclase stimulator are pregnancy category X and
should not be used in pregnancy. If a PAH patient who is taking
one or more of these medications becomes pregnant, their use
should be immediately discontinued (CB).
7. At the time of delivery, iv prostaglandins may be considered
in patients not already treated with this class of medication (CB).
8. At the time of delivery, PAH patients require close monitor-
ing, with a central venous catheter, an arterial line, and careful
attention to volume status (CB).
9. Close monitoring is recommended for all pregnant PAH
patients, with routine evaluation by history, physical examination,
imaging (echocardiography) and laboratory testing as appropriate
for deterioration (CB).
10. Routine monitoring with Swan-Ganz catheterization is not
recommended in the peripartum period because of the risk of
complications. Other techniques to noninvasively assess cardiac
output (CO) in the peripartum period, such as lithium dilution,
can be considered (CB).
From “Role for anticoagulation in
the pregnant PH patient”
1. If a PAH patient has been receiving anticoagulation therapy
before pregnancy, the risks and beneﬁts of this therapy should be
reevaluated and discussed at the time of pregnancy (CB).
2. Warfarin should be stopped and either unfractionated or low-
molecular-weight heparins used if anticoagulation is continued (CB).
3. Prophylactic heparin is recommended in the peripartum pe-
riod (CB).
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4. New oral anticoagulants are currently not recommended for
PAH or chronic thromboembolic PH (CB).
INTRODUCTION
Pulmonary hypertension (PH) has long been recognized to affect
women in substantially greater numbers than men. Epidemiologic
data on pulmonary arterial hypertension (PAH), as classiﬁed by the
ﬁfth World Symposium on Pulmonary Hypertension,1 speciﬁcally
shows that women are affected 3–4 times more commonly than
men.2,3 Progressive pulmonary vascular obliteration in all forms of
PH frequently leads to right heart failure and often to death. Increas-
ing data now suggest a mechanistic role for sex hormones in pul-
monary vascular disease. Moreover, women affected by PH are often
young and of childbearing age.2,3 How pregnancy-induced shifts in
sex hormones may affect pregnant PH patients is currently an area
of intense debate. Further, the physiologic burden of pregnancy in
PH patients is an area of major concern, as it has been linked to
unacceptably high maternal and fetal mortality.4
While expert guidelines on the management of PH rightly cau-
tion that pregnancy is contraindicated in PH,5 occasionally PH is
diagnosed during pregnancy or a PH patient becomes pregnant
despite appropriate warning. Data on the management of the preg-
nant PH patient are limited, and thus recommendations for man-
agement of these situations would serve as helpful guides to clinicians.
We sought to perform a rigorous and extensive literature review and
also convened experts with experience in this topic to generate a
statement regarding the current knowledge of and treatment recom-
mendations surrounding pregnancy in PH. Although it is clear that
there are limited data on this relatively rare yet important clinical
challenge, our document attempts to address current understanding
of sex hormones in pulmonary vascular disease, physiologic effects
of pregnancy in the PH patient, recommendations for pregnancy
avoidance, and management of the pregnant PH patient. Where
evidence is lacking and expert opinion is used, we have noted this
accordingly, in an attempt to help clinicians as they face challenging
PH cases. In addition, we recognize that there may be socioeconomic,
religious, or cultural differences that drive management of preg-
nancy in PH. Through the Pulmonary Vascular Research Institute
(PVRI), we have convened an international collaboration of experts
to address pregnancy in PH. We have collectively attempted to be
sensitive to these issues in crafting our document and to reach con-
sensus in drafting the recommendations, but the reader is cautioned
to implement recommendations appropriate for the culture of the
patient. Finally, because most data are focused on the subset of PH
patients with PAH, this is a focus of our data review, but much of
the statement is applicable to non–WHO group 1 PH.
We have attempted to comprehensively cover the known and
unknown scientiﬁc points as well as clinical management questions,
but we recognize that not all literature on this topic can be dis-
cussed and that the topic is rapidly evolving. The reader is recom-
mended to consult both primary sources and reviews. In future years,
we plan to update this statement, and we also plan to address other
issues related to gender and PH. Our document may point out areas
of great interest for researchers in the ﬁeld. Future studies will hope-
fully address unanswered questions in the management of pregnancy
in PAH and other forms of PH.
METHODS
Recognizing that, despite recommendations to the contrary, preg-
nancy occurs in our female patients with PH, our goal was to pro-
duce a summary statement on pregnancy in PH with a focus on
(1) current knowledge of basic science on sex hormones in PH,
(2) physiology speciﬁc to PH and pregnancy, (3) recommendations
for pregnancy avoidance, and (4) management of the PH patient
during pregnancy. Healthcare providers may use these recommen-
dations to optimize care of the female PH patient, both those who
chose to avoid pregnancy and those who present with known or
newly diagnosed PH and are pregnant.
Our group convened in September 2013 and through conference
calls drafted an outline of this document, focusing on the areas of
interest outlined above. Each author of the document was assigned
a major heading to review literature and draft recommendations.
After an initial draft of the literature was assembled, we met to re-
view ﬁndings and generate recommendations at the PVRI meeting
in Giessen, Germany, in January 2014. After this meeting, each au-
thor composed a set of recommendations for his or her major head-
ing. Although recommendations exist for drafting guidelines,6 our
group recognized that the ﬁeld of pregnancy and PH had insufﬁ-
cient evidence to use the recommended methods for diseases of
greater prevalence and with a larger body of evidence. Instead, we
ﬁrst performed a rigorous literature search within each topic, using
PubMed, then met both via teleconference and in person at the
PVRI meeting. Each author summarized recommendations for clin-
ical care as either evidence based or consensus based (CB).
After an initial draft of recommendations, all CB recommenda-
tions were voted on by the members of the writing committee via
an internet-based polling system (REDCap). To be included in the
ﬁnal document, recommendations required agreement of 7 of 8
authors. Recommendations not meeting this requirement were re-
worded until this threshold was reached.
REVIEW AND RECOMMENDATIONS
Overview of PH classification and pathophysiology
The group of pulmonary hypertensive disorders encompasses a het-
erogeneous entity of diseases that are characterized by a mean pul-
monary artery pressure (mPAP) of ≥25 mmHg.7 The increase in
mPAP may or may not be accompanied by a signiﬁcant increase
in pulmonary vascular resistance (PVR), even though marked in-
creases in PVR are typically observed in more severe precapillary
forms of the disease.8-12 The WHO differentiates 5 major groups of
pulmonary hypertensive disorders that differ in their pathogenesis,
severity, structural abnormalities, prognosis, and treatment strate-
gies (Table 1).1
PAH (WHO group I PH) is one of the most severe types of
pulmonary hypertensive disorder. PAH is a progressive and devastat-
ing disease of multifactorial etiology that eventually results in signiﬁcant
hemodynamic alterations, severe pulmonary vascular remodeling,
increased PVR, RV failure, and death.8-10 Despite the development
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of new pharmacological treatments over the past 2 decades, no cure
exists, and 3-year mortality remains unacceptably high, at 55%.13
The hallmark of PAH is an abnormal and progressive hyperpro-
liferative, antiapoptotic pulmonary vascular remodeling process that
involves all cell types of the pulmonary artery (PA) wall.8-10 Al-
though PAH was initially thought to be a disease primarily charac-
terized by vasoconstriction and abnormal shear stress, it is now
established that the pathogenesis of PA remodeling in PAH is much
more complex and includes genetic abnormalities, epigenetic phe-
nomena, altered microRNA function, enhanced extracellular matrix
deposition and degradation, perivascular inﬂammation, mitochon-
drial dysfunction, and recruitment and activation of circulating and
resident progenitor cells, leading to vascular obstruction with the
formation of plexiform and occlusive lesions.8-10 These alterations
work in concert to generate a profound pulmonary vascular remod-
eling process that shares similarities with malignant cell growth.8-10
Despite the use of advanced therapies, PAH remains a debilitating
and deadly disease,13 and the effectiveness of currently available
PAH treatments is limited because these drugs primarily target the
vasoconstrictive aspect of the disease.14,15 However, while it is gen-
erally accepted that vasoconstriction is important in early stages
and/or milder forms of the disease, the major factor responsible for
the high PVR in severe, established PAH is the formation of occlu-
sive neointimal and plexiform lesions in small, peripheral PAs.8-10
In addition, while PAH is primarily a disease of the small-resistance
PAs of the pulmonary vascular compartment, recent research estab-
lished that the larger-conductance vessels of the pulmonary vascu-
lar system are affected by PAH as well and contribute to disease
pathogenesis and increased PVR by exhibiting altered mechanical
properties (e.g., increased vascular stiffness).8,16-18 Ultimately, the in-
crease in PVR results in RV stress, maladaptive RV remodeling, RV
failure, and death.8-10
WHO group 2 and group 3 PH, while much more common than
PAH, typically is characterized by less severe hemodynamic alter-
ations and PA remodeling.11,12 WHO group 4 and group 5 PH, on
the other hand, may be as severe as PAH and may exhibit struc-
tural and pathogenetic features that overlap with WHO group 1
disease.19,20
Pregnancy in patients with any type of PH is associated with
signiﬁcant morbidity and mortality.21-23 Because of the relatively
high prevalence of PAH in women of childbearing age,13,24 preg-
nancy is a particular challenge in patients with this type of PH. In
particular, pregnancy in women with severe PAH, compared with
that in women with mild PAH, is associated with higher maternal
morbidity and adverse fetal outcomes.25 A detailed understanding
of the effects of pregnancy on the pulmonary vasculature and RV
is therefore of critical importance. The remainder of this section
therefore reviews the currently available data on how pregnancy
affects the pulmonary vasculature, followed by a review of preg-
nancy’s effects on the RV.
Physiologic changes of pregnancy/concerns in PH
The mechanical and hormonal changes of pregnancy affect each
major organ system. These changes are primarily due to (1) me-
chanical compression of the surrounding structures caused by the
enlarging uterus, (2) increases in the levels of sex hormones, and
(3) increases in the circulatory volume. The effects on the major or-
gan systems most relevant to PH (cardiovascular, respiratory, and
hematologic systems) are reviewed here.
Mechanical and hormonal changes in pregnancy. Mechanical
changes in pregnancy. Mechanical changes in pregnancy are pri-
marily due to hormone-mediated changes in maternal chest wall
Table 1. Updated clinical classiﬁcation of pulmonary hypertension (PH)
Group Deﬁnition Selected etiologies
Group 1 Pulmonary arterial hypertension (PAH) Idiopathic PAH,
connective tissue disease–associated PAH,
congenital heart disease–associated PAH,
heritable PAH,
schistosomiasis-associated PAH,
persistent PH of the newborn
Group 2 PH due to left heart disease Left ventricular systolic dysfunction,
left ventricular diastolic dysfunction,
aortic or mitral valvular heart disease
Group 3 PH due to lung diseases and/or hypoxia Chronic obstructive pulmonary disease,
interstitial lung disease,
sleep-disordered breathing,
developmental lung disease
Group 4 Chronic thromboembolic PH
Group 5 PH with unclear multifactorial mechanisms Sarcoidosis,
chronic hemolytic anemia
Note: Adapted from Simonneau et al.1
438 | PVRI statement on pregnancy in PH Hemnes et al.
diameter and enlargement of the uterus, thereby affecting cardiac
and pulmonary function. In addition, in the supine position, blood
ﬂow in the inferior vena cava may be compromised because of uter-
ine compression.
Hormonal changes in pregnancy. Sex hormone levels increase
dramatically during pregnancy and have a major effect on the
body.26-30 The fetoplacental unit formed by the fetus and the placenta
produces all the hormones necessary for a successful pregnancy. Ste-
roid precursors are delivered from both the fetus and the mother.
One of the ﬁrst hormones to peak during pregnancy is plasma
human choriogonadotropin (hCG). This peak occurs in the tenth
week of pregnancy. One of the many effects of hCG is the stimula-
tion of the hormone relaxin, which, like estrogens and progesterone,
mediates vasodilatory responses and facilitates blood ﬂow to crit-
ical organs.31
Progesterone and estrogens are the major sex hormones for the
remainder of the gestation period. Plasma progesterone is initially pro-
duced by the corpus luteum, but its production is taken over by the
placenta during the transition to the second trimester. Progesterone
exhibits a ﬁrst peak in the ﬁrst month of pregnancy, followed by a
sharp and continuous increase throughout the remainder of the
pregnancy, ending with a peak concentration at around 340 pg/mL
immediately before delivery.27,30 The major role of progesterone is
to create a protective environment for the fetus in the uterine cavity
by stimulating endometrial glands to nourish the zygote and by
maintaining the homeostasis of decidual cells. Furthermore, proges-
terone inhibits the occurrence of uterine contractions by decreasing
prostaglandin synthesis and by attenuating sensitivity to oxytocin.
Progesterone also mediates major cardiovascular and respiratory
adaptations in pregnancy (see below).
Levels of the three major estrogens (estrone [E1], 17β-estradiol
[E2], and estrione [E3]) rise steadily throughout pregnancy. E2 levels
reach values of up to 7,200 pg/mL.27,30 Major effects of estrogens
include stimulation of the growth of the myometrium and of the
ductal system of the breast. Like progesterone, estrogens also have
signiﬁcant effects on the cardiopulmonary system (reviewed below).
Other sex hormones increased during pregnancy include prolac-
tin, sex hormone–binding globulin, dehydroepiandrosterone (DHEA),
and testosterone.26-29 Both progesterone and estrogen levels drop
sharply immediately after delivery.
Pregnancy effects on the cardiovascular system. Plasma
volume and dilutional anemia. One of the most signiﬁcant changes
in the cardiovascular system is a signiﬁcant increase in plasma vol-
ume. Plasma volume starts to increase early in pregnancy and peaks
shortly before delivery at values that are 50%–70% above the pa-
tient’s prepregnancy values.32-34 The major cause of the pregnancy-
induced increase in plasma volume is hormone-mediated vaso-
dilation, which leads to underﬁlling of the vascular system and
atria, resulting in activation of the renin-angiotensin-aldosterone
system and a decrease in natriuretic peptide release, allowing for
signiﬁcant retention of sodium and volume (6–8 L).35-38 The latter
is mainly contained in the uterus, breast, muscle, and skin. Red cell
mass increases above the prepregnancy baseline, also as a conse-
quence of increased erythropoietin production, but only by 20%–30%
(and even less so in patients not taking iron supplements).32,39,40
Since red cell mass rises less than the plasma volume, a signiﬁcant
dilutional anemia occurs, with normal hemoglobin values as low as
10.5 g/dL.41 The resultant decrease in blood viscosity facilitates per-
fusion of the fetoplacental unit and may also lower cardiac work.
Cardiac axis, heart size, and heart rhythm. Because of mechan-
ical forces from the enlarging uterus and a resulting upward shift
of the diaphragm, a leftward shift of the cardiac axis occurs. Con-
sequentially, nonspeciﬁc ST and T wave changes can be seen on
an electrocardiogram.42 This is accompanied by mild dilation and
stretching of all cardiac chambers, as well as mild tricuspid regur-
gitation,43,44 changes that are due to the increase in plasma volume.
Left ventricular (LV) mass increases slightly;44,45 however, the ratio
of wall thickness to ventricular radius does not change, indicating
an eccentric hypertrophy similar to what is seen with athletic train-
ing.46 These shifts in cardiac axis and anatomy, in combination
with hemodynamic, hormonal, and autonomic changes, represent
the major causes of the frequently observed benign supraventricular
arrhythmias during pregnancy.47 Similarly, increases in heart rate
by 15–20 beats per minute are common.48,49
CO, systemic vascular resistance, and mean arterial pressure
(Fig. 1). CO rises sharply in the ﬁrst trimester and then increases
more gradually to peak values of around 30%–50% above the
prepregnancy baseline.49-52 Initially, this is mediated by an up to
35% increase in stroke volume (SV). The reason for the increase
in SV is likely multifactorial and due to the increased plasma
Figure 1. Changes in cardiac output (CO), mean arterial pressure
(MAP), and systemic vascular resistance (SVR) during pregnancy.
Values above dotted line represent an increase from baseline, while
values below dotted line depict a decrease.
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volume, decreased afterload, increased contractility, and eccentric
hypertrophy associated with increased LV compliance.46,53 The in-
crease in contractility likely results from a Frank-Starling response
triggered by increased plasma volume and possibly also from di-
rect inotropic effects of sex hormones (e.g., estrogens and prolac-
tin). However, increases in contractility have not been uniformly
described, and transient decreases in systolic function have been
reported as well.54,55 Later in pregnancy, an additional increase in
heart rate contributes to the increases in CO as well. CO values of
up to 8.7 L/min at week 36–38 may be seen.45,56-58 LV ejection
fraction remains unchanged.43,44 B-type natriuretic levels increase
slightly but remain within normal limits.59
Systemic vascular resistance (SVR), on the other hand, decreases
by up to 40% as a consequence of progesterone- and estrogen-
mediated vasodilation as well as the generation of a high-ﬂow and
low-resistance circuit in the uteroplacental circulation; this results
in a signiﬁcant drop in diastolic blood pressure.49,60-64 The mecha-
nisms of hormone-mediated vasodilation are not completely under-
stood but likely include increased endothelial prostacyclin and nitric
oxide production and decreased responsiveness to the vasoconstric-
tive effects of angiotensin II and norepinephrine, as well as reduced
aortic stiffness.65-70 The latter allows for increased compliance of the
vascular system. The structural correlates of these changes include
fragmentation of reticular ﬁbers and changes in the structure of
elastic ﬁbers, as well as hypertrophy and hyperplasia of smooth mus-
cle cells.71
Because of the opposing effects of increased CO and decreased
SVR on mean arterial pressure (MAP), the latter decreases only
slightly. Systolic and diastolic blood pressure may decrease slightly in
the ﬁrst 2 trimesters (to a statistical mean of about 105/60 mmHg);
however, in the third trimester these values usually increase back to
prepregnancy baselines, as does MAP.49,60-64
Pulmonary vasculature (Fig. 2). Changes similar to those in the
systemic vasculature are observed in the pulmonary vascular sys-
tem, where the increase in CO and the decrease in PVR result in
a grossly unchanged mPAP. As in the systemic vasculature, the
decrease in PVR is primarily hormone mediated; recruitment of
previously nonperfused pulmonary vessels (similar to what is seen
during exercise) has been suggested as well. A normal pulmonary
vascular system can therefore easily accommodate the increased CO
and increased pulmonary blood ﬂow that occur during pregnancy
(Fig. 2; upper-right corner). However, in the setting of pulmonary
vascular disease (e.g., PAH or pulmonary embolism), these com-
pensatory mechanisms are signiﬁcantly impaired, resulting in a sig-
niﬁcant afterload stress on the RV (Fig. 2; lower-right corner). The
inability of the pulmonary vasculature to accommodate the in-
creased CO therefore explains the frequent worsening of PH and
the frequent occurrence of RV failure during pregnancy or in the
postpartum period, where CO rises even more (see below).21-23
Effects of labor on the cardiovascular system. While the ﬁrst
9 months of pregnancy are characterized by marked but gradual
changes in the cardiovascular system, labor and delivery are asso-
ciated with even more rapid and dramatic changes. In particu-
lar, the intrathoracic pressure swings and volume shifts associated
with labor and delivery have signiﬁcant effects on cardiac preload
and afterload. For example, the pronounced respiratory efforts as-
sociated with labor and delivery cause signiﬁcant changes in intra-
thoracic pressure, thus leading to marked pressure swings in the
central venous system as well as in the arterial system.72 Further-
more, large volume shifts occur during and after delivery through
the release of vena caval obstruction, as well as through autotrans-
fusion of 300–500 mL of blood from uterine contractions.39,73 A
signiﬁcant additional increase in blood volume is therefore seen
in the peripartum and postpartum periods, accompanied by in-
creases in CO (15%–25% above prelabor values) and SVR.39,73 On
the other hand, postpartum hemorrhage may lead to marked vol-
ume shifts in the other direction, highlighting the complexities of
labor and delivery in patients with pulmonary vascular disease.
Pregnancy effects on the respiratory system. Lung mechan-
ics and gas exchange. Early in pregnancy, structural changes occur
in the thorax to accommodate the enlarging uterus. The circum-
ference of the lower chest wall increases, and the subcostal angle
may increase from 68° to 100° or more in the ﬁrst trimester. The
chest diameter increases by a minimum of 2 cm, resulting in a
“barrel chest” appearance of the thorax.74-76 These changes are due
to the relaxing effects of the hormone relaxin on the ligamentous
attachments of the lower ribs.77 By term, the diaphragm rises up to
4 cm. Interestingly, diaphragmatic excursion is not limited by the
enlarging uterus and increases by up to 2 cm.
Pregnancy is a hypermetabolic state, and oxygen consumption
increases by up to 20%.78 Respiratory adaptations to the increased
oxygen demand are primarily mediated via progesterone-mediated
increases in tidal volume, while respiratory rate does not change
signiﬁcantly.79,80 The underlying mechanisms of progesterone-
mediated hyperventilation are not completely understood; increased
sensitivity of the medulla to carbon dioxide has been suggested, as
Figure 2. Adaptation of the pulmonary vascular system and the
right ventricle (RV) to increased pulmonary blood ﬂow during
pregnancy in a healthy patient and in pulmonary vascular disease.
Note that the diseased pulmonary vasculature in pulmonary ar-
terial hypertension (PAH; characterized by vasoconstriction, pul-
monary vascular remodeling with lumen obliteration, and in situ
thrombosis) is unable to accommodate the increased cardiac out-
put, thus leading to RV strain, dilation, and eventually decompen-
sation. PE: pulmonary embolism.
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well as direct stimulatory effects of progesterone on the respiratory
center.79,81,82 Minute ventilation increases by approximately 50%,
resulting in a respiratory alkalosis that is accompanied by a com-
pensatory metabolic acidosis.79,83-85 The consequence of the increased
alveolar ventilation is a signiﬁcant rise in alveolar and arterial oxy-
gen tension84,86 and also a sense of dyspnea. In fact, up to 70% of
normal pregnant women experience dyspnea during pregnancy.87
The changes in maternal arterial oxygen and carbon dioxide ten-
sions (PaO2 and PaCO2, respectively) facilitate oxygen and carbon
dioxide transfer across the placenta. Normal values for pH, PaO2,
and PaCO2 in pregnancy are provided in Table 2.
Functional residual capacity (FRC) decreases by 20% as a con-
sequence of displacement by the enlarging uterus.88 This is the cor-
relate for the rapid desaturations that occur in pregnant patients
despite the slightly increased PaO2.
Airway anatomy. Upper-airway anatomy is affected by pregnancy-
induced weight gain and by pregnancy-induced ﬂuid retention
and associated oropharyngeal edema; this has signiﬁcant implica-
tions for airway management in pregnant patients, as a difﬁcult
airway situation may arise. This is exempliﬁed by a study demon-
strating an increase by 34% in the number of patients with a
Mallampati class 4 airway from week 12 to week 38.89 In addition,
the process of labor may signiﬁcantly affect airway anatomy. Specif-
ically, a recent study demonstrated that the modiﬁed Mallampati
classiﬁcation increased by 1 grade in 33% of parturients and by
2 grades in 5% of parturients.90 Interestingly, airway edema does
not correlate with the duration of labor or the amount of ﬂuid
administered and may still be present, at least in part, at 48 hours
postpartum.90 The exact cause of this phenomenon is unclear. The
combination of a difﬁcult airway and decreased FRC can make
endotracheal intubation extremely challenging, a scenario that is
especially precarious if the patient has an already compromised
pulmonary vascular bed, as is the case in PH.
Physiologic changes in the postpartum period. The post-
partum period is characterized by a rapid drop in estrogen and
progesterone levels, followed by gradual normalization over 6 weeks.
Blood volume and hematological changes normalize within 6–8
weeks,91 while CO and SVR may take up to 3 months, or even
longer, to reach prepregnancy values.92
Summary. 1. Major physiologic changes of pregnancy in the
cardiovascular system include volume expansion and increased CO,
as well as major volume and pressure swings during and after labor.
2. Pregnancy-induced changes in the respiratory system in-
clude decreased FRC, respiratory alkalosis, and airway edema.
Basic biology of PH and pregnancy
Pregnancy effects on the pulmonary vasculature in PAH.
As reviewed in “Overview of PH classiﬁcation and pathophysiol-
ogy,” the normal pulmonary vasculature responds to pregnancy by
dilating and by recruiting previously nonperfused vessels, resulting
in decreased PVR. Along those lines, the impact of vasoconstrictor
stimuli is attenuated, as evidenced by the observation that preg-
nancy is characterized by attenuated hypoxic vasoconstriction.93,94
Women have a more distensible pulmonary circulation than men;95
however, whether these changes are even more pronounced during
pregnancy is unknown.
While it is unclear how many of the changes observed in the
pulmonary vasculature during pregnancy are directly attributable
to increases in sex hormone levels, there is irrefutable evidence
that sex hormones have many pharmacological inﬂuences on the
pulmonary circulation. For example, E2, testosterone, and proges-
terone all attenuate PA vasoconstriction.96-100 Underlying mecha-
nisms include increases in endothelial nitric oxide synthase activity,
increased prostacyclin synthase activity, and decreased endothelin 1
activation.96,101-106 Interestingly, progesterone receptors have been
identiﬁed in myoﬁbroblasts resident in plexiform lesions.107 Proges-
terone causes pulmonary vasodilation99 and may inhibit vascular
remodeling and attenuate experimental PH.108
The effects of endogenous E2 in PH are largely unknown but
likely to be complex. For example, women are more prone to devel-
oping PAH,13,24 but E2 levels and female sex correlate with higher
RV ejection fraction,109-111 and female sex is associated with better
PAH survival.13,24 E2 has several interesting properties relevant to
PAH pathogenesis. Particularly, in addition to vasodilator effects,
it has proangiogenic and anti-inﬂammatory properties.112 Interest-
ingly, pulmonary microvascular density, markers of angiogenesis,
and diffusion capacity in women vary over the menstrual cycle, and
estrogen replacement in ovariectomized animals increases lung cap-
illarization, thus suggesting that angiogenesis and diffusion char-
acteristics in pregnant patients may be inﬂuenced by E2 and other
sex hormones as well.113 Depending on the context, E2 or its me-
tabolites may exert antiproliferative or proproliferative effects on
vascular endothelial and smooth muscle cells.114-120 The antiprolif-
erative mechanisms have been implicated in protective E2 effects
in animal models of PAH;105,106,112,115,116 whether they play a role
in the adaptation of the pulmonary vasculature to pregnancy, how-
ever, remains unknown.
DHEA exerts a variety of effects on the pulmonary vascula-
ture that include vasodilation and stimulation of antiproliferative
pathways;121-126 increases in this hormone thus would be expected
to facilitate the adaptation of the pulmonary vascular system to
pregnancy-induced hypervolemia. Major effects of sex hormones
on the pulmonary vasculature are depicted in Figure 3.
Table 2. Normal values for pH and arterial
oxygen and carbon dioxide tensions (PaO2
and PaCO2, respectively) in pregnancy
Measure
Normal value
in pregnancy
pH 7.39–7.45
PaCO2, mmHg 25–33
PaO2, mmHg 92–107
Sources: Handwerker et al.;83 Fadel et al.;84
Lim et al.;85 Spiropoulos et al.86
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Relaxin has vasodilator properties in the systemic vasculature31,127
and appears to act as a pulmonary vasodilator as well.127-129 It is
unknown whether the structural changes that are reported in the
systemic vasculature of pregnant subjects (e.g., remodeling of the ex-
tracellular matrix, with changes in the structure of reticular and elastic
ﬁbers71) are also present in the pulmonary vascular compartment, but
a report of relaxin-induced inhibition of collagen accumulation in
the main PAs in a PH model suggests that processes similar to
those in the systemic vasculature may also occur in the pulmonary
vascular component.129
Several other hormones implicated in the pathogenesis of PAH
are further increased by pregnancy. For example, increased prolactin
may play a role in precapillary PAH.130 Speciﬁcally, this hormone
is already signiﬁcantly increased in PAH patients and correlates in-
versely with the 6-minute-walk distance and peak oxygen uptake.
Serum parathyroid hormone can also be elevated in PH.131 Ele-
vated plasma aldosterone levels were reported in PAH patients.132
Finally, pregnancy increases glucocorticoid levels and may lead to
hyperglycemia. In addition, maternal diabetes is a risk factor for
PPHN.133 Hence, pregnancy can upregulate many hormones al-
ready pathogenically elevated in PAH. It is possible that increases
in these pharmacologically active hormones may exacerbate their
deleterious effects on the pulmonary vasculature.
The overarching problem in the pregnant PH patient is that
the physiologic compensatory vasodilator response of the pulmo-
nary vasculature is decreased or absent, thus leading to a signiﬁcant
increase in mPAP and PVR.8-10 The inability of the pulmonary
vascular bed to accommodate the increased CO results in signiﬁ-
cant RV afterload stress, and RV strain and RV failure may occur
(Fig. 3). The resulting hypotension and hypoxemia (the latter po-
tentially exacerbated by increased right-to-left shunting through a
patent foramen ovale) represent major health risks for both the
mother and the fetus; this is reﬂected by the dramatic morbidity
and mortality associated with pregnancy in PAH.21-23 Deterioration
is most frequent between weeks 20 and 24, during labor and deliv-
ery, or in the postpartum period,21-23 as these time points represent
the stages with the most signiﬁcant changes in hemodynamics and
volume status. Deterioration around week 24 reﬂects an inability of
the cardiopulmonary system to accommodate the increased CO
and meet cardiovascular demands, while deterioration during labor
and delivery or in the postpartum phase frequently is triggered by
volume shifts and intravascular pressure swings, as well as the nega-
Figure 3. Pathophysiology of pulmonary hypertension (PH) and right ventricular (RV) dysfunction in pregnancy. Items in red represent
the underlying preexisting alterations in PH; items in blue represent pregnancy-related modiﬁers that may aggravate these alterations.
Potential contributions of sex hormones are shown in yellow (derived from studies in normal animals as well as PH models). Decreased
pulmonary vasodilation and vascular recruitment, as well as hypervolemia and volume shifts, are the major contributors to RV dysfunc-
tion and failure in pregnant PH patients. Volume shifts are primarily due to intermittent mechanical compression of the inferior vena
cava, effects of respiration-induced changes in intrathoracic pressure on venous return, autotransfusion during and after delivery, and
postpartum blood loss. Hypotension, hypoxemia, and arrhythmias may further worsen RV failure and initiate a vicious cycle. DHEA:
dehydroepiandrosterone. *Whether worsening pulmonary vascular remodeling contributes to worsening of PH and RV function during
pregnancy remains unknown. #The contribution of 17β-estradiol (E2) to pulmonary vascular remodeling in PAH is unknown, and in-
hibitory as well as stimulatory effects may exist, depending on the clinical context.
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tive effects of pain, Valsalva maneuvers, hypoxia, and acidosis on
pulmonary vascular tone and/or RV function (Fig. 3). Thromboem-
bolic phenomena may contribute to deterioration in the peripartum
period as well. A recent review of the literature demonstrated that
the majority of maternal deaths occurred in the peripartum period,
mainly within the ﬁrst month of delivery, with RV failure and
circulatory collapse being the main causes of death.21
Since the pulmonary vasculature in PAH is characterized by
nitric oxide and prostacyclin deﬁciency as well as by increased
endothelin 1 activation,8,10 there appears to be a lack of substrate
for sex hormones to initiate their vasodilator properties. Further-
more, there is concern that prosurvival and proproliferative effects
of estrogens may worsen the pulmonary vascular remodeling in
pregnant PAH patients. For example, several studies have demon-
strated proproliferative effects of E2 on PA smooth muscle cells
(PASMCs) in animal models of PH and in human disease.134-137
In premenopausal women, E2 synthesis occurs mainly in the
ovarian follicles and corpus luteum; synthesis also occurs to a
lesser extent in nonglandular tissues such as adipose tissue, liver,
skin, muscle, and brain. In men and postmenopausal women, adi-
pose tissue is a major source of estrogen synthesis.138 Aromatase
(CYP19A1) is a member of the cytochrome P450 (CYP) super-
family and synthesizes E2 through the aromatization of androgens,
speciﬁcally testosterone and androstenedione. Further metabolism
is mediated by several CYP enzymes. In particular, CYP1B1 cata-
lyzes the oxidation of E1/E2 to 2- and 4-OHE2 (2- and 4-hydroxy
estradiol, respectively). E2 hydroxylation can occur by CYP en-
zymes (including CYP1B1), resulting in 6, 7, 15, and 16 (α- and β-)
hydroxyestradiol. E2 can also be converted to (1) E1 by 17β-
hydroxysteroid dehydrogenase and hence via oxidation to 16α-
OHE1, which is mitogenic, or (2) 2-OHE2 by CYP1A1/2, CYP1B1,
and CYP3A4. Catechol-O-methyltransferase (COMT) catalyzes the
methylation of catechol-E2s to methoxy-E2s, which simultaneously
lowers the potential for DNA damage and increases the concentra-
tion of 2 methoxyestradiol, an antiproliferative metabolite. Both
aromatase and CYP1B1 are expressed by human PASMCs and by
the medial layer of human PAs; notably, expression of aromatase is
increased in female PASMCs.139,140 Hence, there is local synthesis
and metabolism of E2 in human PAs. It has also recently been
shown that endogenous E2 contributes to the development of PH
in the female hypoxic mouse and the sugen/hypoxic rat, in part by
restoring impaired bone morphogenetic protein type 2 receptor
(BMPR2) signaling in the female lung.139 This is signiﬁcant, as the
primary genetic defect of heritable PAH (HPAH), present in at least
70% of cases of HPAH, is a mutation in the gene encoding BMPR2,
coupled with dysfunctional Smad signaling that leads to abnormal
cell proliferation associated with pulmonary vascular disease.141
Studies in human PASMCs have also demonstrated that E2 en-
hances other mediators of proproliferative signaling, such as the
mitogenic transcription factors CEBPβ and FOS,137 the calcium-
binding protein S100A4/Mts1,135 and several components of the
serotonin production and transport axis (all of which have been
implicated in PAH pathogenesis).136 A contribution of proprolifer-
ative estrogen metabolites (e.g., 16α-OHE1) to PAH development
has recently been recognized,140,142 and it is possible that excess
production of such metabolites during pregnancy may contribute to
worsening pulmonary vascular remodeling and hemodynamics in
PAH patients. Pregnancy exerts complex effects on the various CYP
isoforms;143 however, whether and how pregnancy affects CYP1B1
expression and activity remain unknown. In addition to genetic
alterations in CYP1B1, two promoter single-nucleotide polymor-
phisms in the gene coding for aromatase that result in elevated E2
production have been associated with an increased risk of porto-
pulmonary hypertension.144
Knowledge gaps. While it is plausible that estrogens and other
sex hormones promote pulmonary vascular remodeling in PAH, it
is unknown whether the frequently observed worsening of PAH in
pregnancy is indeed due to direct effects of sex hormones on the
pulmonary vasculature or merely reﬂects an effect of the hyper-
volemia and volume shifts that are associated with the pregnant
state. Studies investigating whether pulmonary vascular remodeling
indeed progresses in pregnant PAH animals are therefore needed.
Along those lines, the effects of sex hormones on pulmonary vascu-
lar remodeling during pregnancy require further investigation. Simi-
larly, the contribution of estrogen metabolites to PAH development
in pregnancy requires further study. Since worsening of PAH fre-
quently occurs in the postpartum period21-23 and therefore at a
time point at which sex hormone levels decrease dramatically, it is
possible that a “sex hormone withdrawal phenomenon” results in
PA vasoconstriction in the postpartum state. However, this has not
yet been investigated. Studies investigating cyclical changes in vaso-
motor tone related to the menstrual cycle demonstrate worsening
vasoconstriction during periods of low estrogen levels,100,145-147 sug-
gesting that such a phenomenon may contribute at least in part to
the frequent PAH decompensation observed in the postpartum
stage.
Pregnancy effects on the RV in PAH. During pregnancy,
both the LV and the RV exhibit hypertrophic growth in order to
compensate for the increase in blood volume and CO.54 In partic-
ular, these chambers undergo eccentric hypertrophy, a ﬁnding that
is characterized by a proportional change in wall thickness.148
Even though diastolic function may be impaired,44,54 the hyper-
trophy is considered to be physiological (or adaptive), similar
to the cardiac hypertrophy observed in athletes.148,149 While the
SV increases, LV systolic function is maintained,43,44 although tran-
sient decreases in systolic function have been described.54,55 On the
other hand, other studies found no change in LV ejection frac-
tion.43,44 The histological correlate of the increase in heart size and
weight is cardiomyocyte hypertrophy, with an increase in cardio-
myocyte length.148 Pregnancy-induced cardiac hypertrophy is re-
versible and starts to regress soon after delivery.50,54
Cardiac function and remodeling during pregnancy. While the
effects of sex hormones and pregnancy on the LV have been rel-
atively well characterized, these data cannot necessarily be ex-
trapolated to the RV, as the two chambers are embryologically,
anatomically, physiologically, biochemically, and electrophysiolog-
ically different.150,151 However, studies speciﬁcally investigating
the impact of sex hormones and pregnancy on the RV are sparse,
Pulmonary Circulation Volume 5 Number 3 September 2015 | 443
and investigations are needed that speciﬁcally focus on the effect
of these factors on RV structure and function. Studies from the
LV have demonstrated that both mechanical stress associated with
pregnancy-induced hypervolemia and direct effects of sex hor-
mones cause a wide range of changes in the myocardium.152
These include the activation of second messengers such as protein
kinase C, mitogen-activated protein kinase, and Src tyrosine ki-
nase.148 It has been proposed that activation of the latter represents
one of the mechanisms of estrogen-mediated heart hypertrophy
in late pregnancy.148 In addition, E2 has been shown to down-
regulate cardiac Kv4.3 gene expression, an effect that has been
linked to the longer QT interval observed in pregnancy.148
Interestingly, alterations in markers of pathological cardiac hy-
pertrophy—such as α- and β-MHC (myosin heavy chain) switch
or changes in atrial natriuretic peptide, phospholamban, or SERCA
(sarco/endoplasmic reticulum Ca2+-ATPase), all of which have been
implicated in the pathophysiology of RV failure in PAH153,154—
have not been detected in pregnancy.148 Additional studies that
further characterized cardiac hypertrophy in late pregnancy in mice
demonstrated increased cardiac angiogenesis, absence of ﬁbrosis,
and decreased expression of matrix metalloproteinase 2, 15, and
17.155 Despite an increase in cardiac contractility, LV pressures are
increased, suggesting a component of cardiac dysfunction.155 These
changes were reversed in the postpartum period.155 Furthermore,
the myocardium of late pregnancy exhibits decreased proteolytic
activity of the ubiquitin-proteasome system, as well as decreased
oxidative stress.156 The decrease in proteasome activity appears to
be independent of E2 levels.156
Sex hormone effects on cardiac function. A signiﬁcant body of
work has demonstrated protective effects of E2 and/or female sex
in various forms of LV injury, all of which would expected to
beneﬁt RV function in pregnant PH patients. In particular, several
studies in various types of LV injury (e.g., chronic pressure over-
load or myocardial ischemia) have demonstrated protective effects
of E2 and/or female sex on cardiac function and mortality.157-165
These improved outcomes are accompanied by favorable estrogen
receptor–mediated E2 effects on myocardial metabolism, inﬂam-
mation, microRNA signaling, ﬁbrosis, matrix remodeling, and ap-
optosis.157-166 E2 mediates these favorable adaptations to LV injury
by targeting multiple cardiac cell types, such as cardiomyocytes,
endothelial cells, ﬁbrocytes, progenitor cells, and inﬂammatory cells
(reviewed by Murphy167). Interestingly, E2 has consistently been
shown to decrease cardiac hypertrophy in LV injury models and in
in vitro studies,160,164,165,168-170 a ﬁnding that seems to contradict
ﬁndings of E2-mediated increases in cardiac hypertrophy during
pregnancy.148 Differences in the type and duration of cardiac hyper-
trophy (adaptive versus maladaptive) may explain this discrepancy,
at least in part.
Despite a signiﬁcant number of studies investigating effects of
E2 and sex on LV function in pregnancy and disease, how preg-
nancy and sex hormones affect the function and molecular make-
up of the normal RV remains relatively unexplored. Furthermore,
the effects of sex hormones and pregnancy on an already diseased
RV have not been well characterized. In particular, it is unknown
whether and how pregnancy and sex hormones affect physiologi-
cal or biochemical parameters in the RV once these are already
altered by chronic pressure overload. What is currently known is
that both healthy women and women with PAH exhibit RV func-
tion superior to that of their male counterparts.109-111,171 Further-
more, in female hormone-replacement therapy users, RV ejection
fraction correlates with E2 levels, suggesting either a direct effect
of E2 on RV function or a more indirect effect via modiﬁcation of
RV afterload.110 Along those lines, basic-science investigations in
nonpregnant rodents with PH demonstrated protective estrogen
receptor–mediated E2 effects on RV function that are associated with
decreased RV stress signaling, increased RV capillary density, and de-
creased ﬁbrosis as well as with decreased expression of the matrix-
remodeling enzymes ADAM15, ADAM17, and osteopontin.112,115,172
Taken together, these data suggest salutary E2 effects on RV func-
tion in PH. Whether these animal ﬁndings translate to human dis-
ease is currently unknown.
Similarly, DHEA has been shown to exert RV-protective ef-
fects in rodent models of PAH, where its administration was as-
sociated with decreased oxidative stress, decreased apoptosis, and
decreased activation of cardiac-remodeling mediators (e.g., Rho ki-
nase, STAT3, and NFATc3),173 as well as with improved mitochon-
drial bioenergetics and antioxidant mechanisms.174 In humans,
DHEA levels are associated with higher mass and higher RV SVs
in healthy women.110 Testosterone, on the other hand, is associated
with lower RV ejection fraction and higher RV mass in healthy
subjects,110 and testosterone increases RV hypertrophy and ﬁbrosis
in male mice undergoing PA banding.175 Sex hormone effects on
RV function in PAH are summarized in Figure 3.
Hormone-mediated cardioprotection and the peripartum period.
While these studies suggest beneﬁcial effects of major pregnancy
hormones on RV function, they do not, however, explain the high
prevalence of pregnancy-associated RV failure in PAH. One poten-
tial explanation is that despite potential beneﬁcial effects of E2 and
DHEA on RV function, increased testosterone levels during preg-
nancy176,177 negatively affect RV performance. Furthermore, rapid
decreases of E2 and DHEA levels after delivery may contribute to
RV failure in the postpartum stage. In this scenario, the negative
effects on RV function, occurring simultaneously with worsening
pulmonary vasoconstriction, would provide a “perfect storm” and
cause the RV to decompensate. Alternatively (or in addition), the
RV stress associated with the hemodynamic changes and volume
shifts during pregnancy, and particularly the peripartum period,
may “overwhelm” E2- and DHEA-mediated protection and thus
induce RV failure, especially in light of the known transient decrease
in cardiac function that normally occurs during pregnancy.54,55,156
In sum, pregnancy is associated with a number of adaptive
changes in the cardiopulmonary compartment that serve to ac-
commodate the increased CO and to meet the increased cardio-
vascular demands of the pregnant body. In PAH, however, several
of these compensatory mechanisms are attenuated or simply
overwhelmed. Pregnant PAH patients usually die of RV failure and
cardiovascular collapse, with the majority of deaths occurring in the
early postpartum period. The changes in hemodynamics and vol-
ume status observed during pregnancy appear to be a major cause
of the worse outcomes in pregnant PAH patients. The role of sex
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hormones is not yet clear, as some studies show beneﬁcial effects
(e.g., vasodilation) while others suggest that they exert harmful ef-
fects (e.g., proliferation of PASMCs) on the pulmonary vascula-
ture. Data for cardiac function are more clear-cut, as there is a
solid body of evidence that supports beneﬁcial effects of E2 and
DHEA on cardiac function, even though studies speciﬁcally focus-
ing on the RV are sparse and primarily in animals. In addition,
studies investigating the effects of sex hormones speciﬁcally on RV
function in the setting of pregnancy do not exist; this represents
a signiﬁcant knowledge gap in the ﬁeld. The contribution of the
abrupt fall in sex hormones after delivery to the high prevalence of
cardiac decompensation in the postpartum period requires further
investigation.
Effects of pregnancy on non–group 1 PH. The great bulk
of current literature on sex hormone effects on the pulmonary vas-
culature and the potential effects of pregnancy are focused on PAH
(WHO group 1 disease) or on hypoxia-associated PH (group 3).
The effects of sex hormones on WHO group 2, 3, 4, and 5 PH
and their potential effects on the pulmonary vasculature in preg-
nancy are essentially unstudied and are a major knowledge gap at
present.
PPHN: potential maternal influences. Studies suggest a pos-
sible association between maternal use of the selective serotonin-
reuptake inhibitor (SSRI) ﬂuoxetine late in the third trimester of
pregnancy and the risk of PPHN in the infant.178,179 In further
studies it was shown that an increased risk for PPHN was indi-
cated for high maternal age, ﬁrst parity, high maternal body mass
index (BMI), and possibly maternal smoking. Adjusting for these
variables and year of birth, an association between maternal use of
SSRIs and PPHN in births after 34 completed weeks was still
identiﬁed, with a risk ratio of 2.4 (95% conﬁdence interval [95%
CI]: 1.2–4.3) when based on women who reported the drug use
in early pregnancy. When a subgroup of the women who had
prescriptions for SSRIs from the antenatal care later in pregnancy
were studied, the risk ratio estimate was 3.6 (95% CI: 1.2–8.3).180
However, these ﬁndings remain controversial, and some conclude
that, because of sample sizes and quality issues in studies, the
absolute risk cannot be determined.181 If there is a risk, the mech-
anism behind the association between SSRIs and PPHN is unclear,
but an increased risk for respiratory problems after maternal use
of SSRIs is well known, and PPHN could be a rare component
of this association. Possible etiological mechanisms are polymor-
phisms in the promoter alleles of the serotonin transporter gene182
and in enzymes involved in catecholamine metabolism,183 which
may predispose to neonatal adverse effects, including respiratory
distress.184 Experimentally, it has been suggested that prolonged
exposure to SSRIs can induce PPHN through direct effects on the
fetal pulmonary circulation via serotonin. Serotonin causes pulmo-
nary vasoconstriction, contributes to maintenance of high PVR in
the normal fetus, and hence may contribute to the hypertensive
effects of SSRIs.185,186 A recent review concluded that the risk of
PPHN is increased for infants exposed to SSRIs in late pregnancy,
independent of the potential moderator variables examined. Al-
though the statistical association was signiﬁcant, clinically the ab-
solute risk of PPHN remained low even in the context of late
exposure to SSRIs.187
Summary. 1. The overriding problem in PH during pregnancy
is the decreased ability of the pulmonary vasculature to accommo-
date pregnancy-induced increases in CO and circulating blood vol-
ume. This represents a particular problem during labor and delivery,
when additional hemodynamic changes and volume shifts occur and
when other stressors (e.g., catecholamine release, acidosis, hypox-
emia, thromboemboli) may further compromise the pulmonary vas-
cular bed.
2. Consequentially, the postpartum period represents the most
vulnerable time point in pregnant PH patients, with RV failure
representing the most common PH-related complication. An in-
creased risk for clinical deteriorations also exists in the late ﬁrst
trimester and between weeks 20 and 24.
3. The effects of pregnancy-induced increases in sex hormones
on the pulmonary vasculature in PH are complex and incom-
pletely understood. While estrogens may facilitate the adaptation
of the pulmonary vasculature to the increased CO via vasodilation
and may favorably affect RV function, theoretical concern exists
that proproliferative estrogen effects may worsen pulmonary vas-
cular remodeling.
4. The incomplete understanding of the effects of sex hormones
and their metabolites on pulmonary vascular remodeling and RV
function during pregnancy and immediately after delivery repre-
sents a signiﬁcant knowledge gap in the ﬁeld. This should be ad-
dressed in future basic-science and clinical investigations.
5. High maternal age, ﬁrst parity, increased maternal BMI, and
possibly maternal smoking represent risk factors for PPHN. In
addition, available studies suggest a possible association between
maternal use of SSRIs in the third trimester of pregnancy and an
increased risk of PPHN in the infant.
Summary of recommendations. 1. When counseling preg-
nant women or women considering pregnancy, healthcare prac-
titioners should inform them regarding the risks, including possibly
PPHN, and potential beneﬁts of SSRIs (CB).
Clinical research on pregnancy outcomes in PH
PAH has been associated with poor outcomes in nonpregnant
patients. In the era before the availability of PAH-speciﬁc treat-
ments, the National Institutes of Health (NIH) registry for PAH,
which included mostly prevalent patients, reported a 50% survival
rate of 2.8 years,188 while the most recent large national registries in
the era of available multiple therapies report average survival rates
of 50% at 7 years.189-191 It is therefore not surprising to see a dismal
outcome in PAH patients who become pregnant. Deterioration in
pregnancy is reported to occur between the twentieth and twenty-
fourth weeks of gestation, early in third trimester, and in the post-
partum period.22 Sudden hemodynamic instability is associated with
a high maternal mortality. In such cases, RV failure is the most
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common cause of death (“Physiologic changes of pregnancy/con-
cerns in PH” and “Basic biology of PH and pregnancy” above).
The currently available PAH-speciﬁc therapies have affected
survival in nonpregnant PAH patients. Therefore, it is important,
when analyzing the data, to take into account the availability of
speciﬁc drug therapies and the multidisciplinary approach adopted
by most large PH centers. In addition, it is crucial to identify the
experience accumulated in various PH centers around the world,
taking into account the availability of PAH-speciﬁc therapies in dif-
ferent parts of the world. A summary of selected studies reporting
outcomes in the mother and offspring is outlined in Table 3. Given
that in 1996 prostacyclins became available for PAH treatment, we
examine the published experience by separating reports temporally
into pre- and postprostacyclin eras.
Pregnancy outcomes in the preprostacyclin era. In 1996,
epoprostenol was approved for treatment of PAH in the United
States. Although not approved by regulatory agencies outside the
United States, epoprostenol and its analog iloprost have also been
used in Europe and other regions. Historical studies from the pre-
prostacyclin treatment era, including systematic reviews of the pub-
lished literature, identiﬁed a risk of maternal death in the range of
30%–56%.1 In a review of the published literature between January
1978 and December 1996, Weiss et al.4 identiﬁed 73 patients with
Eisenmenger’s syndrome, 27 with idiopathic PAH (IPAH, formerly
called “primary PH”), and 25 with PAH associated with other con-
ditions (formerly called “secondary PH”). All patients, except for 1,
delivered at 32 weeks or later. Pulmonary hypertensive crisis after
oxytocin use occurred in 1 patient. Maternal mortality was 36% in
Eisenmenger’s syndrome, 30% in IPAH, and 56% in associated
PAH. All fatalities, except for 3, occurred within 35 days after deliv-
ery. Late maternal death several months postpartum was reported
in 3 patients with Eisenmenger’s syndrome. The causes of death
were pulmonary hypertensive crisis with therapy-resistant heart
failure (n = 13), sudden death (n = 7), autopsy-conﬁrmed pulmo-
nary thromboembolism (n = 3), cerebral thromboembolism (n = 1),
and rupture and dissection of the PA (n = 1). Previous pregnancies,
timing of diagnosis and hospital admission, operative delivery, and
diastolic PA pressure were signiﬁcant univariate maternal risk
factors. Late diagnosis (P = 0.002, odds ratio: 5.4) and late hospital
admission (P = 0.01, odds ratio: 1.1 per week of pregnancy) were
independent predictive risk factors of maternal mortality. Twenty-
two neonates (weight: 2,372 ± 640 g) survived. One stillbirth and
2 neonatal deaths due to congenital anomalies resulted in a fetal/
neonatal mortality rate of 12% (95% CI: 3%–31%). Of note, 1 par-
turient was treated with heparin and urokinase; operative delivery
was assisted by extracorporeal circulation, and postpartum treat-
ment with coumarin, nifedipine, prostaglandins, and diuretics was
associated with the patient’s survival. Nevertheless, in aggregate,
these data suggest that pregnancy in the preprostacyclin era was
associated with extremely high maternal and fetal morbidity and
mortality.
Pregnancy outcome reports overlapping the pre- and
postprostacyclin eras. Mortality and morbidity in pregnant
PAH patients improved somewhat over the next years but remained
exceedingly high. Bonnin et al.22 reviewed the charts of 14 pregnant
women with 15 pregnancies over a period of 10 years (1992–2002).
The overall mortality in this study was 36% (5 of 14 patients). In
this series, 3 cases of early deterioration occurred, at weeks 12, 20,
and 24 of gestation, in only 1 of which did the patient survive,
suggesting that early deterioration should lead to therapeutic abor-
tion. Five of the seven other cases of deterioration occurred during
the third trimester.
Experience from Japan was reported in 42 pregnant women
who were studied retrospectively from January 1982 to December
2007.192 Patients were divided into mild-PAH (systolic PAP of
30–50 mmHg on echocardiography or mPAP of 25–40 mmHg by
catheterization; n = 14) and severe-PAH (systolic PAP ≥ 50 mmHg
on echocardiography or mPAP ≥ 40 mmHg by catheterization; n =
28) groups. The cohort included mostly patients with IPAH or
congenital heart disease–associated PAH. All patients with severe
PAH before pregnancy had evidence of worsening PA pressures in
their last trimester of pregnancy, while most of those with mild
PAH had mild or no increase in PA pressures, although this latter
group was assessed only by noninvasive methods. Patients with
mild PAH delivered mostly at term, whereas those with severe PAH
had earlier deliveries. The New York Heart Association (NYHA)
functional class worsened in all but 2 patients as pregnancy pro-
gressed. There was 1 death immediately after intubation for delivery.
Although the authors did not report the use of speciﬁc PAH thera-
pies, they mention the use of iv epoprostenol in 3 cases.
Bédard el al.21 conducted a comparative analysis of articles pub-
lished between January 1997 and September 2007. Overall mortality
was 25%. Parturients who received general anesthesia were 4 times
more likely to die than parturients receiving regional anesthesia.
Unlike the report from Weiss et al.,4 primigravidae were at higher
risk of death than parturients with previous pregnancies. Seventy-
eight percent of deaths occurred within 1 month postpartum (15
deaths postpartum vs. 3 deaths during pregnancy). Neonatal/fetal
deaths occurred in 10%, 7%, and 13% of patients with IPAH, con-
genital disease–associated PAH, and patients with associated PAH,
respectively.
Pregnancy outcomes in the era of PAH-specific therapies. Over
the past decade, there have been several reports of patients with
PAH successfully managed during pregnancy, suggesting an im-
proved outcome with current therapies.196-198 This literature, how-
ever, is subject to publication bias, may reﬂect the most successful
management of PAH in pregnancy,199 and should be interpreted
with caution.
In a retrospective series conducted between 1999 and 2009 at 5
US medical centers, experience from 18 pregnant PAH patients was
reported (50% of patients had congenital heart disease).194 Six un-
derwent pregnancy termination at a mean gestational age of 13 ±
1 weeks, with no maternal deaths or complications. Twelve elected
to continue pregnancy. PAH-speciﬁc therapy was administered to
9 (75%) at the time of delivery, consisting of sildenaﬁl, iv pros-
tanoids, or combination therapy. All parturients underwent cesar-
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ean section at 34 weeks. There was 1 in-hospital death and 1 ad-
ditional death 2 months postpartum, responsible for a maternal
mortality rate of 16.7%.
Experience from China is evidenced in a retrospective review
of 30 consecutive parturients with PAH hospitalized at Peking
Union Medical College Hospital from January 1999 to December
2008.200 The majority of patients were transferred to the PH cen-
ter at near-term gestation; therefore, they were not followed in
a center throughout their pregnancy. Eight patients had IPAH, 7
had congenital heart disease–associated PAH, 10 had rheumatic
heart disease–associated PH, and 5 had PH due to other etiologies.
PAH-speciﬁc therapies were used only in 2 patients with congenital
heart disease–associated PAH. The condition of 57% deteriorated
to NYHA classes 3 or 4 during pregnancy. Three patients were
hospitalized, at 16, 18, and 23 weeks of gestation, for therapeutic
abortion because of severe hemodynamic instability, and only 1 sur-
vived. The overall maternal mortality rate was 17%, but patients with
Eisenmenger’s syndrome had 50% mortality. There were 4 fetal/
neonatal deaths (13%), and 16 infants were born preterm. All 26 live-
born infants survived.
Published Portuguese experience consists of 3 cases of IPAH
from a single center.201 One patient had a therapeutic abortion,
but her PAH deteriorated after abortion, with subsequent demise.
The second patient (in whom PAH was well controlled before
pregnancy) died 4 months after therapeutic abortion. A third patient
(a calcium channel blocker long-term responder) underwent cesar-
ean delivery and was managed intraoperatively with iv prostanoid.
Although the patient survived pregnancy and delivery, she ended
up requiring long-term PAH-speciﬁc therapies.
In 2012, Rosengarten et al.202 reported their recent experience
from 7 patients with PAH who had a total of 9 pregnancies and for
whom a careful multidisciplinary approach was implemented. All
but 1 patient were treated with iv prostacyclins, and all underwent
planned cesarean sections at term. Two patients died within 2 weeks
after delivery (22% mortality), and there were no fetal deaths.
In a prospective study from 13 participating centers from Europe,
the United States, and Australia, Jaïs and colleagues23 reported data
from 26 pregnancies between July 1, 2007, and June 30, 2010, and
their 3-year outcomes. During pregnancy, the patients were regu-
larly seen at their PH centers, usually at 2–4-week intervals. Only
one center in France performed right heart catheterizations as part
of their regular assessment during pregnancy. A total of 16 preg-
nancies (62%) were considered successful, deﬁned as survival of the
mother and the baby without complications. Six patients underwent
induced abortion, and 2 had a spontaneous abortion. Both women
with spontaneous abortions died. Three women died in the early
postpartum period as a result of right heart failure, whereas 1 re-
quired urgent heart-lung transplantation. The outcome of pregnan-
cies was better in patients with lower PVR (500 ± 352 dyn-s/cm5),
whereas patients with a very high PVR (1,667 ± 209 dyn-s/cm5)
died or required transplantation. Of note, 8 (50%) of the 16 women
who had successful pregnancies were so-called vasodilator responders
and had nearly normal baseline hemodynamic parameters on cal-
cium channel blocker therapy. The other women with successful
pregnancies were calcium channel blocker nonresponders; how-
ever, most of them had well-controlled PAH while receiving PAH-
speciﬁc therapy. Maternal outcome during the year after delivery
was analyzed for the 16 women who had successful pregnancies.
Two (13%) of them experienced clinical deterioration requiring in-
tensiﬁcation of PAH therapy. Neither was a long-term responder to
calcium channel blockers.
The UK experience is reported in 2 papers. In the earlier re-
port, Kiely et al.195 analyzed retrospectively the management of 10
pregnancies in 9 women who chose to continue with their preg-
nancies between 2002 and 2009 in a specialized PH center. All
women were treated with 4–7 doses of nebulized iloprost per day,
with 2 patients being transitioned to iv prostacyclin and 3 patients
additionally receiving sildenaﬁl. Nine patients underwent planned
cesarean section. All women received regional anesthesia and were
monitored during the peripartum period in a critical care setting.
All women survived the pregnancy and postpartum period, and
all infants were free from congenital abnormalities. One woman
died 4 weeks after delivery, following patient-initiated discontinu-
ation of therapy. Long-term follow-up in the remainder of the
patients was a median of 3.2 years (range: 0.8–6.5 years). A second
UK report describes retrospectively the outcome of 12 pregnancies in
9 women with PAH between 1995 and 2010 at one center.193 All
women delivered by cesarean section (7 elective and 2 emergency
deliveries) under general anesthesia, except for 1 emergency and
1 elective cesarean performed under regional block. There were 2 ma-
ternal deaths (in 1995 and 1998), 1 related to preeclampsia and 1 to
arrhythmia. Maternal morbidity included postpartum hemorrhage
(5 cases) and 1 postcesarean evacuation of a wound hematoma. There
were 9 live births, 3 ﬁrst-trimester miscarriages, and no perinatal
deaths.
A most recent prospective international registry including cen-
ters from the United States and Europe reported on 26 pregnant
PAH patients (17 with IPAH, 9 with associated PAH). Six chose
elective abortion, 16 delivered a healthy baby and survived without
transplantation, and 4 died or underwent urgent transplantation.23
Of the 16 patients who successfully delivered, 2 experienced clinical
deterioration requiring intensiﬁcation of PAH therapy.
Taken together, these data suggest that outcomes of pregnant
patients have improved with the availability of new PAH therapies,
advances in surgical and perioperative management, and use of a
team-based, multidisciplinary approach. However, publication bias
may exist, and despite the availability of new drugs and technolo-
gies, fetal as well as maternal morbidity and mortality remain high.
Summary of recommendations. 1. Although recent studies
suggest improved outcomes in the modern era, maternal morbid-
ity and mortality clearly remain high (CB).
2. In general, patients with PH, particularly PAH, should be
counseled to avoid pregnancy (CB).
3. Given this high mortality rate, rapidly evolving treatment prac-
tices, and the need to make complex decisions, early referral to an
experienced PH center, ideally one with experience in the manage-
ment of PAH in pregnancy, is an essential part of care of the preg-
nant patient with PAH (CB).
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Prepregnancy counseling and contraception
Given the risks associated with pregnancy in PH, avoiding preg-
nancy in the ﬁrst place is imperative. Contraceptive counseling
should begin early after a patient is diagnosed with PH. Depend-
ing on the patient’s personal wishes and cultural expectations, being
informed that pregnancy is contraindicated can be emotionally dev-
astating. The clinician should be ready to provide support. Studies
indicate that women are often not well informed about the neces-
sity of contraception and the available options. For example, in
a study of patients with congenital heart disease performed in
Toronto, Canada, 27 of 80 (34%) of women considered to be at
moderate or high risk for maternal complications during pregnancy
did not recall being informed of their increased risk.203 In a larger
study of 536 patients with congenital heart disease from 2 tertiary
centers in Germany, 20% of women were using a contraceptive
method that was contraindicated for their speciﬁc cardiac condition,
and 28% of patients with high pregnancy-associated risk were not
using contraception at all, despite being sexually active. Furthermore,
43% of patients had not been counseled about contraception, and
48% did not recall being informed about the pregnancy-associated
risks.204 A summary of the efﬁcacy of methods of contraception is in
Table 4.
Hormonal Contraception and IUDs. Estrogen-containing
contraceptives are relatively contraindicated in patients with PAH
because of the increased risk of venous thromboembolic disease
(VTE). A pulmonary embolism is particularly dangerous in this
population. In addition to the concern regarding thromboembolic
disease, exogenous estrogens may contribute to the pathogenesis
of PH. As discussed in “Physiologic changes of pregnancy/concerns
in PH,” the role of sex hormones in the pathogenesis of PH is in-
completely understood, with estrogens appearing protective in some
experimental models and detrimental in others.
Progestin-only contraception methods and IUDs are acceptable
methods for those patients for whom permanent contraception is
either unavailable or unacceptable. Progestin-only contraception meth-
ods are available as pills, injections, implants, or IUDs. However,
concerns exist regarding an increased risk of VTE with injectable
progestins. For example, in an international, multicenter, case-control
study conducted by the WHO in 1989–1993, injectable progestin use
was associated with an odds ratio for VTE of 2.19; however, be-
cause of the wide conﬁdence interval of 0.66–7.26, this did not reach
statistical signiﬁcance.206 On the other hand, a statistically signiﬁcant
risk was found by Vlieg and colleagues.207 In this large case-control
study of women with a history of VTE, use of injectable progestins
was associated with a signiﬁcantly increased risk of VTE (OR: 3.61
[95% CI: 1.8–7.1]). It is worth noting, however, that this ﬁnding was
based on a small number of patients: 20 of the 446 of patients who
presented with VTE were using injectable progestins, versus 15 of
1,146 controls without VTE.207 The study was controlled for age
and family history of VTE. In a recent meta-analysis, Mantha et al.208
reviewed 8 studies (either randomized controlled trials or observa-
tional case-control or cohort studies) to assess the risk of VTE in
women taking progestin-only contraception. Of note, both the WHO
study and the Vlieg study discussed above were included in this
meta-analysis. While the pooled data indicated no increased risk of
VTE associated with either progestin-only pills or progestin-only
IUDs, the injectable progestin formulation (depot methoxyprogesterone)
was associated with a 2-fold increase risk of VTE. These data thus
suggest that the risk of VTE with progestin-only contraception
depends, at least in part, on the administration method.
Progestin-only implants are safe and effective methods of con-
traception. Different formulations are available, with efﬁcacy of
3 years (etonogestrel implant [Nexplanon]), 4 years (levonorgestrel-
implant [Sino-implant]), or 5 years (levonorgestrel implant [Jadelle]).
Efﬁcacy is similar to that of surgical sterilization, and there is no
evidence that these formulations increase thrombotic risk. The im-
plants are placed in the upper arm under local anesthesia.
IUDs are an effective form of contraception for patients with PH.
The two commonly used IUDs are the copper IUD and the progestin-
releasing IUD (Mirena, Bayer HealthCare Pharmaceuticals). Place-
ment of an IUD can be associated with difﬁcult-to-treat vasovagal
reactions when the cervix is manipulated; thus, great caution must
be taken for patients with PAH. As mentioned above, there is no in-
creased risk of VTE with the progesterone-releasing IUDs, and the
rate of uterine blood loss with menses is lower than that with the
copper device. Thus, the progesterone-releasing IUD is favored in
women with PAH. Both devices are associated with an increased
risk of pelvic infections due to sexually transmitted diseases.
It is hypothesized that the lower serum levels of progestin ac-
count for the relative safety of oral and intrauterine progestins, as
compared with progestin injections.208 Peak progestin concentration
after injection is 2,500–7,000 pg/mL, and the level then remains
>400 pg/mL.209 On the other hand, plasma progestin concentrations
Table 4. Efﬁcacy of contraception methods suitable for
patients with pulmonary hypertension
Method
Failure rate,a %
Women
continuing use
at 1 year, %
Typical
use
Perfect
use
Diaphragmb 12 6 57
Progestin-only pill 9 0.3 67
Depo-provera 6 0.2 56
Intrauterine
ParaGard (copper T) 0.8 0.6 78
Mirena (levonorgestrel) 0.2 0.2 80
Progesterone implant 0.05 0.05 84
Female sterilization 0.5 0.5 100
Note: Adapted from Trussell.205
a Women experiencing unintended pregnancy within the ﬁrst
year of use.
b With spermicidal cream or jelly.
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with progestin-releasing IUDs are much lower, with the mean ± SD
plasma concentration of levonorgestrel being 260 ± 68 pg/mL dur-
ing the ﬁrst 3 months and 129 ± 28 pg/mL after 1 year of treat-
ment.210 Concentrations associated with oral formulations are even
lower. Serum levels with progestin-only implants are similar to those
found with progestin-releasing IUDs.211,212
Barrier methods and other methods. Barrier methods of
contraception include diaphragms, cervical caps, and sponges. Be-
cause barrier methods are event driven and often have a higher
failure rate when used alone, they are not recommended as sole
forms of contraception in patients with PH.
Fertility-awareness methods, such as “awareness-based” avoid-
ance of intercourse and lactation-induced amenorrhea, are similarly
ineffective205,213 and are not recommended to prevent pregnancy in
PH patients. Spermicides are among the least effective methods of
contraception and are thus not recommended to be used alone as
contraception in PH.214
Permanent sterilization. Because pregnancy will be danger-
ous for patients with PH for the foreseeable future and because
there is no perfect reversible form of birth control for these women,
some centers favor permanent contraception. Options include
tubal ligation or a device implanted into the fallopian tube (Essure
device, Conceptus, Mountain View, CA). Male sterilization (vasec-
tomy) can be combined with a second form of female birth con-
trol, alternatively.
Tubal ligation can be performed laparoscopically or via a mini-
laparotomy. Both procedures are performed with the patient un-
der general anesthesia with positive-pressure ventilation. Although
commonly used in healthy women, a laparoscopic approach entails
greater risk for the PH patient than for the general population.
Patients are positioned with the head down to shift abdominal con-
tents away from the pelvis, resulting in diaphragmatic impinge-
ment of the thoracic cavity. Furthermore, manipulation of the cervix
is frequently associated with a vasovagal response, and insufﬂation
of carbon dioxide gas into the abdomen causes increased abdominal
pressure and may result in a paradoxical CO2 embolism. For these
reasons, a minilaparotomy may be a safer approach. Although still
requiring general anesthesia, a minilaparotomy is performed in the
supine position, and CO2 insufﬂation is not needed.
Where available, hysteroscopic sterilization is the preferred option
for permanent sterilization. This procedure entails the hysteroscopic
placement of nickel-titanium coils wound around polyethylene ﬁbers
that are inserted into the fallopian tubes. No incision is required.
Patients require minimal or no anesthesia, as frequently conscious
sedation is adequate to perform the procedure. After placement, the
device stimulates an inﬂammatory response that results in tubal oc-
clusion within 10–12 weeks. The procedure is generally safe and
effective, even in high-risk patients. In a retrospective cohort study
of hysteroscopic sterilization, 18 women with severe cardiac dis-
ease, including 5 with PH, were compared with 157 women without
cardiac disease.215 No intraoperative complications were reported,
and follow-up tubal-occlusion rates were 100% in the cardiac group,
compared with 98% in the control group. A report of 4 patients with
PAH described similar outcomes: no procedure or anesthesia-related
complications were encountered.216
Emergency contraception. In cases where emergency contra-
ception is required, hormonal methods may be considered, with
the same caveats discussed above. Alternatively, placement of a
copper IUD has also been reported to be a successful method of
emergency contraception,217 with the added beneﬁts of providing
a lasting method of contraception going forward and avoidance
of exposure to high-dose sex hormones. For patients using the endo-
thelin receptor antagonist bosentan, the dose of emergency contracep-
tion will have to be increased because of the presence of drug-drug
interactions.
Summary of recommendations. 1. All patients should be
counseled to avoid pregnancy, with a thorough explanation of
risks to both mother and fetus (CB).
2. Permanent contraception should be strongly considered in
PAH patients, with recognition that the ﬁeld of PAH therapy is
advancing and that future outcomes may be improved. Therefore,
we recognize that permanent contraception is neither available to
all patients and may not be acceptable to all patients (CB).
3. Of permanent contraception methods, hysteroscopic sterili-
zation is preferred because of the potential for lower procedural
risks (CB).
4. If tubal ligation is planned, a laparoscopic approach is rela-
tively contraindicated because of procedural risks. A minilaparotomy
may be a safer method but still requires general anesthesia (CB).
5. Estrogen-containing contraception is not recommended be-
cause of the increased risk of VTE and the possible deleterious
effects of estrogen on the pulmonary vasculature (CB).
6. Progestin-only pills may be used, but often a second method is
required because of the relatively high “typical-use” failure rate (CB).
7. Progestin-only IUDs and implants are acceptable non-
permanent contraception (CB).
8. Injected progestins (depo-provera) are relatively contrain-
dicated because of a likely increased risk of thrombotic events (al-
though risk is likely to be mitigated if anticoagulants are used in
this population). However, this method may be appropriate in
patients without a history of VTE, because of its superior efﬁcacy to
oral progestin-only pills, when the other, more effective methods
listed above are not available (CB).
9. Barrier and fertility awareness–based methods are not rec-
ommended to prevent pregnancy in PH (CB).
10. Centers managing patients with PH should have access to
family-planning services able to give specialist advice (CB).
Genetic counseling in PH
Genetic counseling in IPAH and HPAH. Mutations in
BMPR2 can be found in about 80% of families affected by
HPAH.218,219 Other genetic mutations have recently been identi-
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ﬁed in HPAH, including caveolin 1 (CAV1),220 KCNK3,221 and
EIF2AK4,222 that further explain a proportion of the remaining
20% of HPAH. Extensive research in the past decade has focused
on the epidemiology of HPAH and downstream signaling associ-
ated with BMPR2 mutation, but there is no cure at present for
this genetic mutation, and patients with HPAH are treated simi-
larly to patients with IPAH. The BMPR2 mutation is a dominant-
negative gene with only weak penetrance, such that approximately
only 20% of people with the mutation will develop PAH while the
remaining 80% do not develop clinical PAH.218,219
In addition, a small percentage of patients with IPAH also
have a BMPR2 mutation but do not have any family members
affected by PAH, because of either the low penetrance or de novo
mutations.223 These IPAH patients with BMPR2 mutation can,
however, transmit the mutation to their biologic offspring, who
are at risk to develop PAH if they receive this allele. The frequen-
cies of the other genes associated with HPAH in the IPAH popu-
lation are unknown at present. Germ-line genetic mutations have
not been described in non–group 1 PH and in PAH that is not
idiopathic or heritable.
Clinically available genetic testing can detect most BMPR2 muta-
tions, and some facilities detect CAV1, ALK1, and KCNK5. Others,
such as EIF2AK4 and other newly discovered mutations, are screened
for only in the research setting at present.
Given the complexity of genetics in HPAH and IPAH, patients
wishing to become pregnant should be offered genetic counseling
before conception. In the process of genetic counseling, patients
will be aided in understanding the risks and beneﬁts of genetic
testing and will then be equipped to make an informed decision
regarding whether or not they want to undergo genetic testing.
They may also consider forms of preimplantation genetic testing
or postconception testing for the fetus if they decide to pursue
pregnancy. Given the potential psychological and ﬁnancial risk
associated with genetic testing, it is not recommended to undergo
genetic testing in the absence of genetic counseling.
Genetic counseling in patients with PAH other than idio-
pathic or heritable and non–group 1 PH. Patients with
other forms of PAH or non–group 1 PH are not recommended to
undergo genetic counseling or testing for BMPR2 mutation unless
there are unusual circumstances.
Summary of recommendations. 1. Genetic counseling should
be offered to patients with IPAH or HPAH (CB).
2. Genetic testing should not be performed in the absence of
genetic counseling (CB).
3. As genetic mutations underlying WHO Groups 2, 3, 4, and
5 PH and PAH not due to idiopathic or heritable disease have not
been described, genetic testing and/or counseling is not required
at present for these conditions (CB).
Pregnancy management
Pregnancy can occur in patients with PH in a number of cir-
cumstances. Despite appropriate counseling, the PH patient may
desire pregnancy and choose to pursue this. Alternatively, patients
may be unaware that they have PH and may present with an initial
diagnosis of PH during pregnancy. Below are recommendations for
pregnancy management, separated by trimester and delivery, based
in part on the European Society of Cardiology guidelines on preg-
nancy in cardiovascular disease.224
Therapeutic abortion. Because of the excessive risk to the
mother and fetus discussed in “Basic biology of PH and preg-
nancy,” when pregnancy occurs in PH patients, termination should
be offered regardless of WHO FC or other markers of progno-
sis.225 Discussion of therapeutic abortion, using a shared-decision
model, has been proposed to establish a common set of goals and
optimize maternal medical care.225 The ﬁrst trimester is the safest
time for elective pregnancy termination; however, in the PH pa-
tient, pregnancy termination carries greater risk than in the general
population and should be performed in an experienced center.224,226
Uterine dilatation and evacuation is the safest procedure.227 If surgi-
cal evacuation is not feasible, medical abortion using prostaglan-
dins E1 or E2 or misoprostol, a synthetic prostaglandin structurally
related to prostaglandin E1, can be administered to evacuate the
uterus.227 These drugs are absorbed into the systemic circulation and
can lower SVR and blood pressure and increase heart rate; these
effects are greater with prostaglandin E2 than with E1.
227
While therapeutic abortion is most commonly performed dur-
ing the ﬁrst trimester in the pregnant PH patient, it should also be
considered in the second trimester up to the point of fetal viabil-
ity. After that point, early delivery may be considered if clinically
indicated. Different cultural and/or religious preferences and legal
obligations are present in the diverse countries of pregnant PH
patients. These factors may inﬂuence timing, acceptability, and
options for therapeutic abortion.
First trimester. Despite strong recommendations for thera-
peutic abortion, some pregnant PH patients may decide to con-
tinue pregnancy. In this case, management should be provided by
a multidisciplinary team in a center experienced in the treatment
of not just PH patients but also pregnant PH patients. At the min-
imum, the team should include a PH specialist, a cardiologist, an
obstetrician, an anesthetist specialized in managing high-risk preg-
nancies, and a neonatologist.195,224-226 Pharmacists, intensivists, and
social workers are frequently needed as well. In addition, in the
case of associated forms of PAH, specialists in the underlying dis-
ease should be involved. Patient-speciﬁc multidisciplinary manage-
ment plans should be put in place.195
A careful baseline assessment of pregnancy risk during this
trimester should include history and physical examination, echocar-
diography, brain natriuretic peptide measurement, and 6-minute-
walk testing. A discussion of PAH-directed therapy in pregnancy
follows in “Role for PAH-directed therapy in pregnancy and deliv-
ery.” Patients should be followed closely, typically monthly, but
assessment frequency should be tailored to individual patients and
their risks. During the ﬁrst trimester, the volume changes associated
with pregnancy are less pronounced than those in future trimesters;
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thus, edema and swelling symptoms should trigger an evaluation of
PH status. As discussed above in “Physiologic changes of pregnancy/
concerns in PH,” hormonal changes associated with early pregnancy
may alter pulmonary vascular disease and precipitate worsening.
Even in the absence of symptoms, regular assessment of PH status is
advisable, using, in addition to physical examination, echocardiogra-
phy, brain natriuretic peptide, 6-minute-walk testing, or a combina-
tion of all at regular intervals during this trimester. Management of
PAH-speciﬁc therapy is discussed in “Genetic counseling in PH.”
Second trimester. As discussed in “Physiologic changes of
pregnancy/concerns in PH,” a major change in the second trimester
is volume expansion and increase in CO, which is achieved in part
through vasodilation and recruitment of the pulmonary vascular bed.
In most forms of precapillary PH (WHO groups 1, 3, 4, and 5), the
diseased pulmonary vasculature cannot accommodate the increased
CO. Patients with group 2 PH may also have difﬁculty accommo-
dating increased ﬂow though the pulmonary vasculature. As a con-
sequence, RV volume loading and subsequent failure may occur.
A dilated RV can, in turn, reduce left heart ﬁlling, thus further
compromising CO. As a function of these volume demands, de-
compensation often occurs in the second trimester, corresponding
to peak blood volume and CO.194 Vigilant follow-up though the pre-
viously discussed multidisciplinary team is essential, and frequency
of visits may have to be increased to every 2 weeks, for example. As
in the ﬁrst trimester, follow-up evaluation should include history
and physical examination, 6-minute-walk testing, and brain natri-
uretic peptide measurement. Echocardiography frequency may be
increased to every 2 weeks if concerns arise during this trimester of
worsening right heart function.
In patients who have developed right heart failure symptoms,
standard therapy including diuretics, oxygen therapy if indicated,
and, for patients with severe symptoms or failure of outpatient
therapy, hospitalization may be considered. In patients requiring di-
uretics, furosemide is preferred, as spironolactone has antiandrogenic
properties and is pregnancy category D.224 As with all right heart
failure, judicious ﬂuid restriction, low-salt diet, and oxygen supple-
mentation are indicated228 where appropriate. To avoid caval vein
compression, the patient should be advised to lie in the lateral po-
sition. Management of PAH-speciﬁc therapy is discussed below in
“Role for PAH-directed therapy in pregnancy and delivery.”
Third trimester. As the major volume expansion has occurred
in the second trimester, the third trimester’s main concerns are
preparation for delivery and ensuring continued safety of the
mother and fetus. In the third trimester, weekly follow-up is sug-
gested (Fig. 4). In this trimester, echocardiograms are recom-
mended every 1–2 weeks to monitor the cardiac status and adjust
PH medications (Fig. 4). As in the second trimester, important
nonpharmacologic therapy involves limiting sodium and ﬂuid intake
during pregnancy.228 Limiting daily ﬂuids to 1.5–2 L, restricting so-
dium intake, and administering diuretics in the third trimester can
reduce RV overdistention and avoid cardiac decompensation. Elec-
tive cesarean section is advisable when the fetus becomes viable. A
multidisciplinary approach has been reported to lead to a favorable
maternal-fetal outcome.195 Close communication between high-risk
obstetrician, anesthesiologist, and PH physician help in the proper
and timely management of these high-risk patients.195
Delivery. The mode of delivery should be carefully selected in
the pregnant PH patient, as it may inﬂuence the outcome. Cesar-
ean section is the preferred mode of delivery.224 Although vaginal
delivery is usually associated with fewer bleeding complications
and infections in the healthy population,229 the hemodynamic and
physiological changes associated may be detrimental to the mother
with PH. The advantages and disadvantages of different modes of
delivery are discussed below.
Monitoring and general considerations during delivery. During
labor and delivery, continuous monitoring of electrocardiogram,
pulse oximetry, central venous pressure, and intra-arterial blood
pressure should be routine.224 While PA catheterization may be of
beneﬁt in selected cases, there is no consensus regarding its rou-
tine use during delivery.21 Several centers manage patients with
central lines and close monitoring of RV function (e.g., by echocar-
diography). The use of noninvasive hemodynamic monitoring in
this setting may be of beneﬁt but has not yet been validated. Close
attention must be paid to avoiding conditions that may lead to PA
vasoconstriction and worsening RV function; these include hyp-
oxia, hypercarbia, and acidosis. Hemodynamically relevant arrhyth-
mias should be aggressively corrected. Anxiety- and pain-induced
catecholamine release may negatively affect hemodynamics; the
use of different anesthetic methods is discussed in detail below. In
order to optimize oxygen delivery as much as possible, signiﬁcant
anemia should be corrected. The patient should be as euvolemic
as possible, and major ﬂuid shifts must be avoided as much as
possible. Vasopressors and inotropes should be readily available for
hemodynamic support. Intravenous prostacyclins should be read-
ily available; however, the role and management of PAH-speciﬁc
medications during delivery is discussed in detail in “Role for PAH-
directed therapy in pregnancy and delivery.” Individualized man-
agement plans for each patient must be discussed and updated be-
fore delivery.
Vaginal delivery. This mode of delivery is usually avoided in
PAH patients, as it carries a multitude of disadvantages. First,
vaginal delivery is associated with frequent use of the Valsalva
maneuver, which increases intrathoracic pressure and thus de-
creases venous return. As the CO in PH patients requires ade-
quate preload, the Valsalva maneuver may critically and rapidly
decrease preload and thus precipitate cardiopulmonary collapse.
Second, labor-induced vasovagal responses can decrease the ve-
nous return and lead to cardiopulmonary collapse. Third, the pain
of childbirth may lead to sympathetic nervous system stimulation.
As a result, there may be an increase in heart rate and increases in
systemic and pulmonary vascular tone, with resultant hemody-
namic instability. Labor-induced acidosis, hypercapnea, or hypoxia
may further contribute to increases in PA pressures. After delivery
of the fetus, an increase in maternal blood volume occurs because
of autotransfusion of blood from the contracting uterus and from
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shifting of peripheral edema from the extravascular compartment
into the systemic vasculature. In addition, venous return may in-
crease from the relief of inferior vena cava obstruction by the gravid
uterus. Finally, agents used to induce labor may precipitate clinical
deterioration. Low-dose oxytocin can be used with caution to in-
duce labor, as it can increase PVR. Because of the potential for
hemodynamic instability due to the aforementioned factors, vaso-
pressor or inotropic support may be required. If vaginal delivery is
chosen, effective analgesia is imperative. Nitrous oxide should be
avoided because of its potential to vasoconstrict the pulmonary vas-
culature,230 and epidural analgesia should be considered.
Cesarean section. Cesarean section is the preferred mode of deliv-
ery and should be used unless not available or in cases of emergen-
cies.22,195 Cesarean section bypasses the hemodynamic complications
associated with labor discussed above and also the autotransfusion
associated with vaginal contractions. Elective cesarean section avoids
labor and allows for careful, multidisciplinary planning and prepara-
tion of anesthesia, optimization of hemodynamics, and development
of contingency plans. Moreover, cesarean section does not appear to
negatively inﬂuence patient outcomes.197 The choice of anesthesia is
important when cesarean section is being considered and should be
preplanned during early multidisciplinary meetings with the anes-
thesiologist, who should be aware of the hemodynamic changes as-
sociated with PH (often an obstetric or cardiac anesthesiologist), and
with an experienced maternal-fetal medicine specialist. The aim
of the anesthesiologist is to achieve an optimum balance between
anesthesia and side effects. Most obstetric units would consider re-
gional anesthesia in preference to general anesthesia for this proce-
dure. This will reduce risks associated with general anesthesia (e.g.,
endotracheal intubation and positive-pressure ventilation, which
may increase PVR and RV afterload). However, a regional approach
is not always possible, and plans should be made to proceed with
general anesthesia if necessary.
Timing of delivery. The optimal timing of planned elective de-
livery in women with PAH is uncertain and involves an assessment of
the maternal risk of continuing pregnancy and risk of neonatal pre-
term delivery. In stable women, planned delivery around weeks 34–
36 is recommended, with delivery before this if there is evidence of
symptomatic decline.
Anesthesia in pregnant PH patients. General anesthesia.
General anesthesia is known to depress cardiac contractility, in-
crease PVR via positive-pressure ventilation, and increase PAP dur-
ing laryngoscopy and intubation.231 Studies by Bédard and others21
suggest that parturients who receive general anesthesia were more
likely to die than parturients receiving regional anesthesia. How-
ever, caution should be shown when interpreting these results, as
selection bias may be shown toward the sicker parturient receiv-
ing general anesthesia. If general anesthesia is required, the patient
should be ventilated with the lowest airway pressure and tidal vol-
ume possible. A lung-protective ventilation strategy similar to what
is used in patients with acute respiratory distress syndrome has been
advocated.232 However, care must be taken to avoid hypercarbia. Cate-
cholamines and iv prostacyclins should be readily available for these
Figure 4. Recommended evaluation of and follow-up for a pregnant patient with pulmonary arterial hypertension (PAH). BNP: brain
natriuretic peptide; ETRA: endothelin receptor antagonist; FC: World Health Organization function class; ICU: intensive care unit;
LMWH: low-molecular-weight heparin; PH: pulmonary hypertension; RV: right ventricular; 6MWT: 6-minute walk test.
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patients, and the administration of catecholamines before anesthe-
sia induction should be considered.
Epidural or combined spinal-epidural anesthesia. Epidural anes-
thesia with incremental doses has traditionally been considered
the best approach to regional anesthesia. However, with the advent
of modern equipment and techniques, low-dose combined spinal-
epidural anesthesia is being increasingly used, because it provides a
denser perineal sensory block than epidural anesthesia alone, with
little additional risk of hypotension.233
Spinal anesthesia. Single-dose spinal anesthesia should be avoided
in this patient population because of the risk of a rapid rise in block
height that may cause uncontrollable hemodynamic instability as
sympathetic block rises and systemic hypotension occurs.22
Postpartum and long-term effects. In the hours and days
after childbirth, blood volume is increased by autotransfusion of
blood from the contracting uterus and by shifting of peripheral
edema from the extravascular compartment into the systemic vas-
culature. In healthy subjects, these physiologic changes are normally
well tolerated, but in the presence of severe pulmonary vascular
disease, hemodynamic instability may develop, leading to cardio-
respiratory failure and/or sudden death.194,224 Parturition and the
ﬁrst postpartum week have been recognized as particularly vulnera-
ble periods for patients with PAH.23,194 Two systematic literature
reviews have described the outcome of pregnancy in women with
PH, covering a total of almost 30 years and comprising 198 preg-
nancies. The mortality of women with Eisenmenger’s syndrome (N =
102) was 36% in the ﬁrst review (1978–1996)4 and 28% in the second
review (1997–2007).21 Most of these women died in the ﬁrst month
after delivery, and the main causes of death were heart failure and
sudden death, while pulmonary thromboembolism was another fre-
quent cause. In women with IPAH (N = 56), mortality was 30% in
the ﬁrst4 and 17% in the second21 review. Similarly, nearly all fatali-
ties in these patients occurred early in the postpartum period, and
death was mainly due to heart failure, followed by sudden death
and thromboembolism. Thus, the immediate postpartum period is
a critical period for acute decompensation in PH patients. Patients
should be closely monitored for several days postpartum; monitor-
ing in an intensive care unit in the ﬁrst few days after delivery is
recommended. This is especially pertinent to high-risk patients, par-
ticularly those with right heart failure or evidence of hemodyanmic
instability during delivery. Prophylactic anticoagulation is important
in this period (see “Role for anticoagulation in the pregnant PH
patient”).234 As the volume expansion that occurs in pregnancy is
sustained for up to 24 weeks postpartum, improvement in functional
status after delivery may take several months.
Detrimental effects of vagal reactions in pregnant pa-
tients with PH. Vagal reactions and syncope can have cata-
strophic consequences in PH patients independent of the presence
or absence of pregnancy, because they may be associated with a
profound drop in CO.235 However, in pregnant PH patients, the
presence of a vagal reaction is particularly concerning, as the RV is
extremely preload dependent and compensatory mechanisms are
even more limited than in nonpregnant PH patients. It is therefore
of utmost importance that potential inducers of vagal stimuli be
recognized and avoided.
Vasovagal syncope is characterized by a temporary reduction
of blood ﬂow to the brain that is caused by sudden hypotension,
change in heart rate, and/or change in blood volume or its distribu-
tion.236 In general, because of their vasodilatory state, pregnant
women are more prone to vasovagal syncope than their nonpreg-
nant counterparts.237 Since PH patients are more prone to syncope
than healthy individuals,235 the combination of pregnancy and PH
therefore creates a “perfect storm,” generating a condition where
(1) vasovagal syncope is more prevalent and (2) its consequences
are particularly dangerous. Common inducers of vagal reactions dur-
ing pregnancy include vena cava compression, rapid positional
changes (especially getting up too fast), pain, anxiety, straining while
pushing during vaginal delivery, hypovolemia, anemia, hyperther-
mia, and hyperventilation. Iatrogenic causes include administration
of vasodilators, interventions that induce vasodilation and decrease
venous return (e.g., induction of general or spinal anesthesia), ma-
nipulation of the cervix, and any procedure that causes pain and/
or anxiety. Common preceding symptoms of vasovagal syncope in-
clude nausea, diaphoresis, lightheadedness, and pallor.
Because of the potential catastrophic consequences of vasova-
gal syncope in the pregnant PH patient, it is of utmost importance
that triggers of such events be avoided as much as possible. If the
trigger is unavoidable or has already occurred, rapid and focused
intervention is critical. Counseling of the pregnant PH patient on
inducers and symptoms of vasovagal syncope, as well as on ap-
propriate interventions, is of highest importance. Similarly, medi-
cal professionals need to be aware of interventions known to raise
vasovagal tone, and they need to be educated that PH patients are
particularly susceptible to such reactions. If patients undergo any
procedure that may induce vagal reactions, such as placement of
an IUD or therapeutic abortion, physicians should place 2 iv lines
and have atropine in the procedure room ready to administer.
Summary of recommendations. 1. Pregnancy in PAH
patients is associated with a high maternal mortality rate. The highest-
risk periods are the peripartum period and the immediate postpartum
period (up to 2 months) (CB).
2. A multidisciplinary approach with high-risk obstetricians,
PH physicians, cardiologists, anesthesiologists, and neonatologists
is recommended (CB).
3. Close clinical monitoring, including monthly follow-up visits
in the ﬁrst and second trimesters and weekly clinic visits in the
third trimester, is recommended (CB).
4. All pregnant PH patients should be offered pregnancy termi-
nation. In particular, patients with worsening right heart failure,
especially early in their pregnancy, and patients with other high-
risk features should be given the option to have their pregnancy
terminated. If patients want to continue pregnancy, augmentation
of PAH therapy should be considered to improve the chances of a
favorable outcome (CB).
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5. Cesarean section is the preferred mode of delivery and should
be used unless not available or in cases of emergencies (CB).
6. Epidural or spinal-epidural anesthesia is recommended rather
than general anesthesia (CB).
7. Because of the potential for catastrophic consequences, preg-
nant PH patients and their providers should be counseled on in-
ducers and symptoms of vasovagal syncope. Triggers of vasovagal
syncope should be avoided (CB).
Role for PAH-directed therapy in pregnancy and
delivery
Patients may present for the ﬁrst time in pregnancy with PAH, or
women with known PAH may actively plan pregnancy despite ap-
propriate counseling regarding the high risks of maternal death. Fi-
nally, PAH patients may accidentally become pregnant. If the woman
chooses to continue pregnancy, there is emerging literature report-
ing on the use of speciﬁc PAH therapies in pregnancy.23,194-199 Three
classes of drugs are currently available for PAH treatment. Calcium
channel blockers have also been used when appropriate.
Prostaglandins. Prostaglandins are potent pulmonary vasodi-
lators that may also act to enhance RV function.238,239 Currently
available parenteral prostaglandins—epoprostenol, treprostinil, and
iloprost—are not known to be teratogens (Table 5) and are listed as
pregnancy category B (epoprostenol and treprostinil) or C (iloprost).
They may thus be continued in patients who receive this class of
medication before pregnancy, if treating physicians and patients
agree that the beneﬁts outweigh the relatively unknown risks. Pre-
pregnancy use of prostaglandins, however, may be an indicator of a
patient with more severe disease. In addition to the usual indications
to begin prostaglandin therapy, such as WHO FC III or IV symp-
toms and reduced RV function,14,240,241 other considerations in preg-
nancy may compel therapy with parenteral prostaglandins. Examples
are worsening symptoms or deteriorating RV function despite ther-
apy with phosphodiesterase inhibitors and nonparenteral prostanoids.
It should be recognized, however, that even with parenteral pros-
tanoids, maternal mortality may still be signiﬁcant.202 In many cen-
ters, iv prostanoids are managed exclusively by the PH specialist; this
includes accompanying the patient to the operating room.
In general, parenteral prostaglandins are recommended for preg-
nant patients with PAH in WHO FC IV or where there is evidence
of severe RV impairment. In selected patients in WHO FC III fol-
lowed in specialized centers, a trial of therapy with nebulized ilo-
prost and addition of sildenaﬁl has been successfully reported.195
When delivered by the parenteral route, gradual up-titration can be
performed as per the usual protocol. Inhaled iloprost or trepros-
tinil may be used in patients with less severe symptoms, and their
safe and successful use in pregnancy has been reported.195,198 How-
ever, in a patient experiencing deterioration while receiving inhaled-
prostaglandin therapy, rapid conversion to parenteral forms (some
publications have advocated for iv epoprostenol242) should be con-
sidered. If there is no rapid clinical improvement, immediate deliv-
ery should be considered because of the high risk of maternal death.
In addition, inhaled epoprostenol or nitric oxide243 has been ad-
ministered continuously to acutely ill patients as a bridge to paren-
teral treatment initiation.
Phosphodiesterase 5 inhibitors. Both sildenaﬁl and tadalaﬁl
are pregnancy category B (Table 5). There are several reports of
successful pregnancies managed with sildenaﬁl either alone or in
combination with a prostaglandin.23,193,194,244,245 The use of tadalaﬁl
in pregnancy has not been reported. In larger case series of success-
ful pregnancies, sildenaﬁl has generally been used in combination
with a prostaglandin.23,194,195 As there is no published experience
with tadalaﬁl, we recommend a preference for sildenaﬁl when phos-
phodiesterase inhibitors are used in pregnancy. Their use, however,
should be restricted to either combination therapy with a prosta-
glandin or, if as a monotherapy, restricted to patients who have
normal RV function and near-normal pulmonary hemodynamics
or who refuse prostaglandin therapy. If phosphodiesterase inhibitor
monotherapy is used, close follow-up for deterioration is indicated.
Calcium channel blockers. PAH patients who have an acute
response to inhaled vasodilators such as nitric oxide (deﬁned by a
drop in mPAP by 10 mmHg to 40 mmHg or less with preserved
CO) are candidates for treatment with calcium channel blocker
therapy and have a substantially improved prognosis, compared to
patients without an acute vasodilator response.246 Durable re-
sponse to calcium channel blocker therapy during pregnancy has
Table 5. FDA-assigned risk category for PAH medications
Drug Pregnancy risk categorya
Epoprostenol B
Treprostinil B
Sildenaﬁl B
Tadalaﬁl B
Nitric oxide C
Iloprost C
Bosentan X
Ambrisentan X
Macitentan X
Riociguat X
Note: FDA: US Food and Drug Administration; PAH: pulmo-
nary arterial hypertension.
a B: animal reproduction studies have failed to demonstrate a
risk to the fetus, and there are no adequate, well-controlled studies
in pregnant women; C: animal reproduction studies have shown an
adverse effect on the fetus, and there are no adequate, well-controlled
studies in humans, but potential beneﬁts may warrant use of the
drug in pregnant women despite potential risks; X: studies in ani-
mals or humans have demonstrated fetal abnormalities, and/or there
is positive evidence of human fetal risk based on adverse-reaction
data from investigational or marketing experience, and the risks in-
volved in use of the drug in pregnant women clearly outweigh po-
tential beneﬁts.
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been described.23 In fact, among the patients included in the only
prospective registry of pregnant PAH patients, 8 of 16 patients
who successfully delivered a baby and survived without trans-
plantation were acute vasodilator responders.23 Calcium channel
blockers are considered safe in pregnancy.247 For those patients
meeting strict criteria for an acute response to inhaled nitric ox-
ide, we recommend therapy with calcium channel antagonists14,246
and close follow-up, as discussed above. In pregnant PAH patients
not meeting these strict criteria, there is no role for calcium chan-
nel antagonists. In this setting, calcium channel blockers may be
detrimental because of their nonselective vasodilatory effects, with
a concomitant drop in SVR, which, in the presence of an inade-
quate CO, may lead to circulatory collapse.
Endothelin receptor antagonists. Endothelin receptor antagonists
(ambrisentan, bosentan, macitentan, and sitaxentan) are pregnancy
category X (Table 5) and should be discontinued when a pregnancy
is discovered in a patient with PAH, because of the known teratoge-
nicity of these medications.
Soluble guanylate cyclase stimulator. Riociguat is pregnancy
category X and should be discontinued when a pregnancy is discov-
ered in a PAH or chronic thromboembolic PH (CTEPH) patient.
Summary for PAH-directed therapy during pregnancy. The
advent of new therapies for PAH provides the clinician and the
patient with a number of choices during pregnancy. These include
the timing of treatment initiation in treatment-naive patients, the
type of drug to be used, and the mode of drug delivery. Varied
approaches in PH centers experienced in the management of PH
in pregnancy reﬂect individual center experience, and where clear
evidence of the beneﬁt of one approach over another is lacking,
pragmatic approaches will reﬂect local experience.195 It should be
recognized that, despite improved outcomes and potential theoreti-
cal beneﬁts of various treatment approaches, the medical treatment
of PAH patients should be carefully chosen and individualized to
take into account the severity of illness, comorbidities, social and
cultural aspects, patient’s wishes, and long-term goals.
Special considerations at delivery. The approach to the use
of PAH therapies around the time of delivery will be inﬂuenced by
the therapies that the patient has been taking during her pregnancy,
her stability before planned delivery, and her progress in the peri-
partum period. When titrating these therapies, one needs to appreci-
ate the physiological changes that are normally occurring in pregnant
women and to be receptive to possible worsening of the pulmonary
vascular disease and the effects of drugs used in the peripartum pe-
riod. Oxytocic drugs, for example, can induce hypotension and tachy-
cardia and should always be given by slow infusion.
Key to allowing titration of these therapies is careful monitoring
of patients during the peripartum period in a high-acuity environ-
ment. Insertion of a central venous catheter to allow measurement of
central venous pressure and sampling of blood to assess central ve-
nous saturation and insertion of an arterial line for measurement of
blood pressure and blood gas sampling are highly recommended.248
Swan-Ganz catheterization is not routinely used because of the risk
of complications, but it can be considered in highly selected cases.
Noninvasive measures of CO, such as lithium dilution, can be used
to titrate treatment in patients with PAH.195,248,249 This can allow a
continuous measure of CO in addition to displaying systemic pres-
sures, heart rate, and other core variables. However, its use has not
been validated in prospective studies.
For stable patients receiving iv prostanoids, doses would usually
remain unchanged before and during delivery. For patients not re-
ceiving parenteral prostanoids, a low-dose infusion of iv prostanoid
started several hours before a planned cesarean section would allow
the physician to assess the hemodynamic effects of this infusion
and avoid problems associated with initiating prostanoids in the
immediate peripartum period, when, in an unstable patient, it may
be difﬁcult to discern side effects of the drug from pulmonary he-
modynamic instability. In these cases, a Swan-Ganz catheter may
help assess the therapeutic effects of infused prostacyclins. If pa-
tients are receiving oral sildenaﬁl, consideration should be given to
using the iv preparation of the drug, particularly if there are any
concerns regarding absorption, which can occur postoperatively, for
example, following the development of ileus after cesarean section.
For surgery under regional anesthesia, patients receiving nebulized
iloprost or treprostinil therapy may continue to nebulize during the
procedure, in addition to receiving a low-dose iv infusion during
the peripartum period. Alternatively, nebulized epoprostenol may
be substituted for intermittent inhalation of iloprost or treprostinil.
The treatment goals during delivery are to maintain systemic
and right atrial pressures, to monitor ﬂuid balance, and to avoid
volume overload, particularly in the ﬁrst 48 hours. A rising right
atrial pressure after delivery may simply reﬂect ﬂuid overload and
can be managed by judicious use of diuretic therapy. If a patient’s
condition deteriorates with falling central venous saturation, rising
right atrial pressure, and other features suggesting worsening of
pulmonary vascular status, then increasing the dose beyond the
background dose of iv prostanoid is usually appropriate, sometimes
coupled with inotropic therapy, such as low-dose dobutamine. For
patients developing hypotension, a cause should be sought, such as
bleeding, sepsis, or low-output heart failure due to increasing after-
load. In this setting, once volume status has been optimized, drugs
such as vasopressin or noradrenaline should be considered.250
While the treatment recommendations above assume access to
PAH therapy, in locations where the full complement of PAH-
directed therapy is not available, supportive care should be insti-
tuted. Such care is discussed in “Pregnancy management” above.
Summary of recommendations. 1. In patients who are in
WHO FC IV or have evidence of severe RV impairment, paren-
teral prostaglandins are recommended. Most published experience
in parenteral prostaglandins is with iv epoprostenol (CB).
2. In select patients with more preserved RV function who are
in WHO FC III, inhaled prostaglandins may be considered. Most
published experience in inhaled prostaglandins is with iloprost.
An appropriate treatment response needs to be veriﬁed (CB).
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3. Oral phosphodiesterase 5 inhibitors may be considered in
patients who are in WHO FC I or II and who have normal RV
function. Most published experience is with sildenaﬁl. Close follow-
up for deterioration is highly recommended for patients treated
with phosphodiesterase 5 inhibitor monotherapy (CB).
4. Parenteral prostaglandins can be combined with oral phos-
phodiesterase inhibitors in pregnancy. Successful outcomes have
been reported with this regimen (CB).
5. For patients meeting strict criteria for vasodilator-responsive
PAH who are not in WHO FC IV and who do not have RV
dysfunction, calcium channel blocker therapy may be continued
in pregnancy, with close follow-up for deterioration (CB).
6. The currently available endothelin receptor blockers and sol-
uble guanylate cyclase stimulator are pregnancy category X and
should not be used in pregnancy. If a PAH patient who is taking
one or more of these medications becomes pregnant, their use
should be immediately discontinued (CB).
7. At the time of delivery, iv prostaglandins may be considered
in patients not already treated with this class of medication (CB).
8. At the time of delivery, PAH patients require close monitor-
ing, with a central venous catheter, an arterial line, and careful
attention to volume status (CB).
9. Close monitoring is recommended for all pregnant PAH
patients, with routine evaluation by history, physical examination,
imaging (echocardiography) and laboratory testing as appropriate
for deterioration (CB).
10. Routine monitoring with Swan-Ganz catheterization is not
recommended in the peripartum period because of the risk of com-
plications. Other techniques to noninvasively assess CO in the peri-
partum period, such as lithium dilution, can be considered (CB).
Role for anticoagulation in the pregnant PH patient
Anticoagulation is recommended for many forms of PAH, includ-
ing IPAH, HPAH, and some forms of congenital heart diseases–
associated PAH,14,224,240,241 in particular for patients with CTEPH
(WHO group 4). Low-molecular-weight heparin is usually used in
patients who receive chronic anticoagulation, and prophylactic
heparin is recommended for all PAH patients in the peripartum
period. When low-molecular-weight heparin is used during preg-
nancy, it may be switched to unfractionated heparin during the
preparation for delivery to facilitate rapid discontinuation when in-
dicated. CTEPH patients should continue anticoagulation during
pregnancy. Warfarin is a known teratogen and is contraindicated in
pregnancy. New oral anticoagulants (e.g., dabigitran, rivaroxaban,
and apixaban) are pregnancy category C, and their use in PAH and
CTEPH has not been studied; thus, they are not recommended.
Summary of recommendations. 1. If a PAH patient has
been receiving anticoagulation therapy before pregnancy, the risks
and beneﬁts of this therapy should be reevaluated and discussed at
the time of pregnancy (CB).
2. Warfarin should be stopped and either unfractionated or low-
molecular-weight heparins used if anticoagulation is continued (CB).
3. Prophylactic heparin is recommended in the peripartum pe-
riod (CB).
4. New oral anticoagulants are currently not recommended for
PAH or CTEPH (CB).
FUTURE DIRECTIONS
There has been tremendous progress in the ﬁeld of pulmonary
vascular disease in the past several decades, which has led to
newer therapies, better mechanistic understanding of disease, and
improved outcomes.190 With continued research and experience,
there is hope for even greater advances in the future. Major areas
of research currently include the effects of sex hormones on PH
and the mechanisms of PH in non–group 1 disease. The effects of
pregnancy on the pulmonary vasculature and RV, particularly in
non–group 1 PH, should be a major focus of research, given the
burden of this disease on young women, children, and families
across the world. Another area of uncertainty as outcomes im-
prove in this disease is the recommendation for permanent sterili-
zation in PH, as more efﬁcacious therapy may be available within
a younger PAH patient’s years of potential fertility. Finally, pro-
spective evaluation of management strategies for pregnant PAH
patients is needed in order to optimize diagnostic and therapeutic
strategies, although such trials are unlikely to occur, given the rel-
ative infrequency of pregnancy in this rare condition.
CONCLUSIONS
Despite major advances in the care of PH patients and the advent
of several classes of medications to treat this condition, PH in gen-
eral and PAH in particular remain highly mortal, and pregnancy is
poorly tolerated. This document summarizes the current knowledge
on pregnancy in PH, with a focus on PAH, as the greatest amount
of literature is available for this disease state. While we continue to
strongly recommend avoidance of pregnancy in patients with PH,
there are situations in which patients may present in pregnancy or
become pregnant, and it is our hope that this document will serve
as a useful reference to practitioners caring for the pregnant patient
with PH. In the future, research into non–group 1 PH, further
understanding of the effects of sex hormones on the pulmonary
vasculature and the right heart, and more effective treatment of
pulmonary vasculature are promising avenues to improve the out-
comes for the pregnant patient with PH.
Source of Support: Nil.
Conﬂict of Interest: None declared.
REFERENCES
1. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C,
Ghofrani A, Gomez Sanchez MA, et al. Updated clinical classiﬁcation
of pulmonary hypertension. J Am Coll Cardiol 2013;62(25 suppl.):
D34–D41.
2. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW,
Frost AE, Barst RJ, et al. Pulmonary arterial hypertension: baseline char-
acteristics from the REVEAL Registry. Chest 2010;137(2):376–387.
3. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin
V, Yaïci A, et al. Pulmonary arterial hypertension in France: results
458 | PVRI statement on pregnancy in PH Hemnes et al.
from a national registry. Am J Respir Crit Care Med 2006;173(9):
1023–1030.
4. Weiss BM, Zemp L, Seifert B, Hess OM. Outcome of pulmonary
vascular disease in pregnancy: a systematic overview from 1978 through
1996. J Am Coll Cardiol 1998;31(7):1650–1657.
5. Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, Klepetko
W, et al. Updated treatment algorithm of pulmonary arterial hyper-
tension. J Am Coll Cardiol 2013;62(25 suppl.):D60–D72.
6. Kuehn BM. IOM sets out “gold standard” practices for creating
guidelines, systematic reviews. JAMA 2011;305(18):1846–1848.
7. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D,
Kurzyna M, Langleben D, et al. Deﬁnitions and diagnosis of pulmo-
nary hypertension. J Am Coll Cardiol 2013;62(25 suppl.):D42–D50.
8. Tuder RM, Archer SL, Dorfmüller P, Erzurum SC, Guignabert C,
Michelakis E, Rabinovitch M, Schermuly R, Stenmark KR, Morrell
NW. Relevant issues in the pathology and pathobiology of pulmo-
nary hypertension. J Am Coll Cardiol 2013;62(25 suppl.):D4–D12.
9. Tuder RM, Stacher E, Robinson J, Kumar R, Graham BB. Pathology
of pulmonary hypertension. Clin Chest Med 2013;34(4):639–650.
10. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hyper-
tension. J Clin Invest 2012;122(12):4306–4313.
11. Vachiéry JL, Adir Y, Barberà JA, Champion H, Coghlan JG, Cottin
V, De Marco T, et al. Pulmonary hypertension due to left heart
diseases. J Am Coll Cardiol 2013;62(25 suppl.):D100–D108.
12. Seeger W, Adir Y, Barberà JA, Champion H, Coghlan JG, Cottin V,
De Marco T, et al. Pulmonary hypertension in chronic lung diseases.
J Am Coll Cardiol 2013;62(25 suppl.):D109–D116.
13. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V,
Yaïci A, et al. Survival in patients with idiopathic, familial, and
anorexigen-associated pulmonary arterial hypertension in the mod-
ern management era. Circulation 2010;122(2):156–163.
14. Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV,
Rubin LJ, Sitbon O, Tapson VF, Galiè N. Updated evidence-based
treatment algorithm in pulmonary arterial hypertension. J Am Coll
Cardiol 2009;54(1 suppl.):S78–S84.
15. Ghofrani HA, Barst RJ, Benza RL, Champion HC, Fagan KA,
Grimminger F, Humbert M, et al. Future perspectives for the treat-
ment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54
(1 suppl.):S108–S117.
16. Lammers SR, Kao PH, Qi HJ, Hunter K, Lanning C, Albietz J,
Hofmeister S, Mecham R, Stenmark KR, Shandas R. Changes in the
structure-function relationship of elastin and its impact on the proxi-
mal pulmonary arterial mechanics of hypertensive calves. Am J Physiol
Heart Circ Physiol 2008;295(4):H1451–H1459.
17. Lammers S, Scott D, Hunter K, Tan W, Shandas R, Stenmark KR.
Mechanics and function of the pulmonary vasculature: implications
for pulmonary vascular disease and right ventricular function. Compr
Physiol 2012;2(1):295–319.
18. Tedford RJ, Hassoun PM, Mathai SC, Girgis RE, Russell SD, Thiemann
DR, Cingolani OH, et al. Pulmonary capillary wedge pressure augments
right ventricular pulsatile loading. Circulation 2012;125(2):289–297.
19. Kim NH, Delcroix M, Jenkins DP, Channick R, Dartevelle P, Jansa P,
Lang I, et al. Chronic thromboembolic pulmonary hypertension. J Am
Coll Cardiol 2013;62(25 suppl.):D92–D99.
20. Lahm T, Chakinala MM. World Health Organization group 5 pul-
monary hypertension. Clin Chest Med 2013;34(4):753–778.
21. Bédard E, Dimopoulos K, Gatzoulis MA. Has there been any prog-
ress made on pregnancy outcomes among women with pulmonary ar-
terial hypertension? Eur Heart J 2009;30(3):256–265.
22. Bonnin M, Mercier FJ, Sitbon O, Roger-Christoph S, Jaïs X, Humbert
M, Audibert F, Frydman R, Simonneau G, Benhamou D. Severe pulmo-
nary hypertension during pregnancy: mode of delivery and anesthetic
management of 15 consecutive cases. Anesthesiology 2005;102(6):1133–
1137; discussion 5A–6A.
23. Jaïs X, Olsson KM, Barberà JA, Blanco B, Torbicki A, Peacock A,
Vizza CD, Macdonald P, Humbert M, Hoeper MM. Pregnancy out-
comes in pulmonary arterial hypertension in the modern management
era. Eur Respir J 2012;40(4):881–885.
24. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ,
Coffey CS, Frost A, et al. Predicting survival in pulmonary arterial hy-
pertension: insights from the Registry to Evaluate Early and Long-Term
Pulmonary Arterial Hypertension Disease Management (REVEAL).
Circulation 2010;122(2):164–172.
25. Subbaiah M, Kumar S, Roy KK, Sharma JB, Singh N. Pregnancy out-
come in women with pulmonary arterial hypertension: single-center
experience from India. Arch Gynecol Obstetr 2013;288(2):305–309.
26. Acromite MT, Mantzoros CS, Leach RE, Hurwitz J, Dorey LG.
Androgens in preeclampsia. Am J Obstetr Gynecol 1999;180(1):60–63.
27. Carranza-Lira S, Hernández F, Sánchez M, Murrieta S, Hernández A,
Sandoval C. Prolactin secretion in molar and normal pregnancy. Int
J Gynaecol Obstetr 1998;60(2):137–141.
28. Larrea F, Méndez I, Parra A, Espinosa de los Monteros A. Serum
pattern of different molecular forms of prolactin during normal hu-
man pregnancy. Hum Reprod 1993;8(10):1617–1622.
29. Montelongo A, Lasunción MA, Pallardo LF, Herrera E. Longitudinal
study of plasma lipoproteins and hormones during pregnancy in
normal and diabetic women. Diabetes 1992;41(12):1651–1659.
30. O’Leary P, Boyne P, Flett P, Beilby J, James I. Longitudinal assess-
ment of changes in reproductive hormones during normal pregnancy.
Clin Chem 1991;37(5):667–672.
31. Novak J, Danielson LA, Kerchner LJ, Sherwood OD, Ramirez RJ,
Moalli PA, Conrad KP. Relaxin is essential for renal vasodilation dur-
ing pregnancy in conscious rats. J Clin Invest 2001;107(11):1469–1475.
32. Pritchard JA. Changes in the blood volume during pregnancy and de-
livery. Anesthesiology 1965;26(4):393–399.
33. Bernstein IM, Ziegler W, Badger GJ. Plasma volume expansion in
early pregnancy. Obstetr Gynecol 2001;97(5):669–672.
34. Lund CJ, Donovan JC. Blood volume during pregnancy: signiﬁcance
of plasma and red cell volumes. Am J Obstetr Gynecol 1967;98(3): 393–
403.
35. Schrier RW. Pathogenesis of sodium and water retention in high-
output and low-output cardiac failure, nephrotic syndrome, cirrhosis,
and pregnancy. Pt. 2. N Engl J Med 1988;319(17):1127–1134.
36. Nadel AS, Ballermann BJ, Anderson S, Brenner BM. Interrelationships
among atrial peptides, renin, and blood volume in pregnant rats. Am J
Physiol Regul Integr Comp Physiol 1988;254(5):R793–R800.
37. Lindheimer MD, Katz AI. Sodium and diuretics in pregnancy. N
Engl J Med 1973;288(17):891–894.
38. Brown MA, Whitworth JA. The kidney in hypertensive pregnancies—
victim and villain. Am J Kidney Dis 1992;20(5):427–442.
39. Ueland K. Maternal cardiovascular dynamics. VII. Intrapartum blood
volume changes. Am J Obstetr Gynecol 1976;126(6):671–677.
40. Milman N, Graudal N, Nielsen OJ, Agger AO. Serum erythropoietin
during normal pregnancy: relationship to hemoglobin and iron status
markers and impact of iron supplementation in a longitudinal, placebo-
controlled study on 118 women. Int J Hematol 1997;66(2):159–168.
41. Milman N, Bergholt T, Byg KE, Eriksen L, Hvas AM. Reference intervals
for haematological variables during normal pregnancy and postpartum
in 434 healthy Danish women. Eur J Haematol 2007;79(1):39–46.
42. Oram S, Holt M. Innocent depression of the S-T segment and ﬂat-
tening of the T-wave during pregnancy. J Obstetr Gynaecol Br Em-
pire 1961;68(5):765–770.
43. Katz R, Karliner JS, Resnik R. Effects of a natural volume overload
state (pregnancy) on left ventricular performance in normal human
subjects. Circulation 1978;58(3):434–441.
44. Mesa A, Jessurun C, Hernandez A, Adam K, Brown D, Vaughn WK,
Wilansky S. Left ventricular diastolic function in normal human preg-
nancy. Circulation 1999;99(4):511–517.
45. Poppas A, Shroff SG, Korcarz CE, Hibbard JU, Berger DS, Lindheimer
MD, Lang RM. Serial assessment of the cardiovascular system in nor-
mal pregnancy. Role of arterial compliance and pulsatile arterial load.
Circulation 1997;95(10):2407–2415.
Pulmonary Circulation Volume 5 Number 3 September 2015 | 459
46. Simmons LA, Gillin AG, Jeremy RW. Structural and functional
changes in left ventricle during normotensive and preeclamptic preg-
nancy. Am J Physiol Heart Circ Physiol 2002;283(4):H1627–H1633.
47. Shotan A, Ostrzega E, Mehra A, Johnson JV, Elkayam U. Incidence
of arrhythmias in normal pregnancy and relation to palpitations,
dizziness, and syncope. Am J Cardiol 1997;79(8):1061–1064.
48. Clark SL, Cotton DB, Lee W, Bishop C, Hill T, Southwick J, Pivarnik
J, et al. Central hemodynamic assessment of normal term pregnancy.
Am J Obstetr Gynecol 1989;161(6):1439–1442.
49. Robson SC, Hunter S, Boys RJ, Dunlop W. Serial study of factors
inﬂuencing changes in cardiac output during human pregnancy. Am
J Physiol Heart Circ Physiol 1989;256(4):H1060–H1065.
50. Robson SC, Hunter S, Moore M, Dunlop W. Haemodynamic
changes during the puerperium: a Doppler and M-mode echocardio-
graphic study. Br J Obstetr Gynaecol 1987;94(11):1028–1039.
51. Capeless EL, Clapp JF. Cardiovascular changes in early phase of preg-
nancy. Am J Obstetr Gynecol 1989;161(6):1449–1453.
52. van Oppen AC, Stigter RH, Bruinse HW. Cardiac output in normal
pregnancy: a critical review. Obstetr Gynecol 1996;87(2):310–318.
53. Moran AM, Colan SD, Mauer MB, Geva T. Adaptive mechanisms of
left ventricular diastolic function to the physiologic load of pregnancy.
Clin Cardiol 2002;25(3):124–131.
54. Schannwell CM, Zimmermann T, Schneppenheim M, Plehn G, Marx
R, Strauer BE. Left ventricular hypertrophy and diastolic dysfunction
in healthy pregnant women. Cardiology 2002;97(2):73–78.
55. Geva T, Mauer MB, Striker L, Kirshon B, Pivarnik JM. Effects of
physiologic load of pregnancy on left ventricular contractility and re-
modeling. Am Heart J 1997;133(1):53–59.
56. Rang S, van Montfrans GA, Wolf H. Serial hemodynamic measure-
ment in normal pregnancy, preeclampsia, and intrauterine growth re-
striction. Am J Obstetr Gynecol 2008;198(5):519e1–519e9.
57. Moertl MG, Ulrich D, Pickel KI, Klaritsch P, Schaffer M, Flotzinger
D, Alkan I, Lang U, Schlembach D. Changes in haemodynamic and
autonomous nervous system parameters measured non-invasively
throughout normal pregnancy. Eur J Obstetr Gynecol Reprod Biol 2009;
144(suppl. 1):S179–S183.
58. Pandey AK, Banerjee AK, Das A, Bhawani G, Kumar A, Majumadar
B, Bhattacharya AK. Evaluation of maternal myocardial performance
during normal pregnancy and post partum. Indian Heart J 2010;62
(1):64–67.
59. Resnik JL, Hong C, Resnik R, Kazanegra R, Beede J, Bhalla V, Maisel A.
Evaluation of B-type natriuretic peptide (BNP) levels in normal and
preeclamptic women. Am J Obstetr Gynecol 2005;193(2):450–454.
60. Ayala DE, Hermida RC, Mojón A, Fernández JR, Silva I, Ucieda R,
Iglesias M. Blood pressure variability during gestation in healthy and
complicated pregnancies. Hypertension 1997;30(3):611–618.
61. Clapp JF III, Capeless E. Cardiovascular function before, during, and
after the ﬁrst and subsequent pregnancies. Am J Cardiol 1997;80(11):
1469–1473.
62. Grindheim G, Estensen ME, Langesaeter E, Rosseland LA, Toska K.
Changes in blood pressure during healthy pregnancy: a longitudinal
cohort study. J Hypertension 2012;30(2):342–350.
63. Hermida RC, Ayala DE, Mojón A, Fernández JR, Silva I, Ucieda R,
Iglesias M. High sensitivity test for the early diagnosis of gestational
hypertension and preeclampsia. I. Predictable variability of cardio-
vascular characteristics during gestation in healthy and hypertensive
pregnant women. J Perinat Med 1997;25(1):101–109.
64. Ochsenbein-Kölble N, Roos M, Gasser T, Huch R, Huch A, Zimmer-
mann R. Cross sectional study of automated blood pressure measure-
ments throughout pregnancy. BJOG 2004;111(4):319–325.
65. Knock GA, Poston L. Bradykinin-mediated relaxation of isolated ma-
ternal resistance arteries in normal pregnancy and preeclampsia. Am
J Obstetr Gynecol 1996;175(6):1668–1674.
66. Weiner CP, Thompson LP. Nitric oxide and pregnancy. Semin
Perinatol 1997;21(5):367–380.
67. Edouard DA, Pannier BM, London GM, Cuche JL, Safar ME. Ve-
nous and arterial behavior during normal pregnancy. Am J Physiol
Heart Circ Physiol 1998;274(5):H1605–H1612.
68. Gant NF, Worley RJ, Everett RB, MacDonald PC. Control of vas-
cular responsiveness during human pregnancy. Kidney Int 1980;18(2):
253–258.
69. Goodman RP, Killam AP, Brash AR, Branch RA. Prostacyclin pro-
duction during pregnancy: comparison of production during normal
pregnancy and pregnancy complicated by hypertension. Am J Obstetr
Gynecol 1982;142(7):817–822.
70. Curran-Everett D, Morris KG Jr., Moore LG. Regional circulatory
contributions to increased systemic vascular conductance of pregnancy.
Am J Physiol Heart Circ Physiol 1991;261(6):H1842–H1847.
71. Manalo-Estrella P, Barker AE. Histopathologic ﬁndings in human aortic
media associated with pregnancy. Arch Pathol 1967;83(4):336–341.
72. Bonica JJ, McDonald JS. Principles and practice of obstetric analgesia
and anesthesia. 2nd ed. Baltimore: Williams & Wilkins, 1994.
73. Kjeldsen J. Hemodynamic investigations during labour and delivery.
Acta Obstetr Gynecol Scand 1979;58(suppl. 89):18–249. doi:10.3109
/00016347909155655.
74. Gilroy RJ, Mangura BT, Lavietes MH. Rib cage and abdominal vol-
ume displacements during breathing in pregnancy. Am Rev Respir Dis
1988;137(3):668–672.
75. Turner AF. The chest radiograph in pregnancy. Clin Obstetr Gynecol
1975;18:65–74.
76. Weinberger SE, Weiss ST, Cohen WR, Weiss JW, Johnson TS. Preg-
nancy and the lung. Am Rev Respir Dis 1980;121(3):559–581.
77. Goldsmith LT, Weiss G, Steinetz BG. Relaxin and its role in preg-
nancy. Endocrinol Metab Clin N Am 1995;24(1):171–186.
78. Prowse CM, Gaensler EA. Respiratory and acid-base changes during
pregnancy. Anesthesiology 1965;26(4):381–392.
79. Liberatore SM, Pistelli R, Patalano F, Moneta E, Incalzi RA, Ciappi
G. Respiratory function during pregnancy. Respiration 1984;46(2):
145–150.
80. Yannone ME. Plasma progesterone levels in normal pregnancy, labor,
and the puerperium. I. Method of assay. Am J Obstetr Gynecol
1968;101(8):1054–1057.
81. Skatrud JB, Dempsey JA, Kaiser DG. Ventilatory response to medroxy-
progesterone acetate in normal subjects: time course and mechanism.
J Appl Physiol 1978;44(6):939–944.
82. Milne JA. The respiratory response to pregnancy. Postgrad Med J 1979;
55(643):318–324.
83. Handwerker SM, Altura BT, Altura BM. Serum ionized magnesium
and other electrolytes in the antenatal period of human pregnancy.
J Am Coll Nutr 1996;15(1):36–43.
84. Fadel HE, Northrop G, Misenhimer HR, Harp RJ. Acid-base determi-
nations in amniotic ﬂuid and blood of normal late pregnancy. Obstetr
Gynecol 1979;53(1):99–104.
85. Lim VS, Katz AI, Lindheimer MD. Acid-base regulation in pregnancy.
Am J Physiol 1976;231(6):1764–1769.
86. Spiropoulos K, Prodromaki E, Tsapanos V. Effect of body position
on PaO2 and PaCO2 during pregnancy. Gynecol Obstetr Invest 2004;
58(1):22–25.
87. Milne JA, Howie AD, Pack AI. Dyspnoea during normal pregnancy.
Br J Obstetr Gynaecol 1978;85(4):260–263.
88. Bonica JJ. Maternal respiratory changes during pregnancy and partu-
rition. Clin Anesth 1974;10(2):1–19.
89. Pilkington S, Carli F, Dakin MJ, Romney M, De Witt KA, Doré CJ,
Cormack RS. Increase in Mallampati score during pregnancy. Br J
Anaesth 1995;74(6):638–642.
90. Boutonnet M, Faitot V, Katz A, Salomon L, Keita H. Mallampati
class changes during pregnancy, labour, and after delivery: can these be
predicted? Br J Anaesth 2010;104(1):67–70.
91. Hellgren M. Hemostasis during normal pregnancy and puerperium.
Semin Thromb Hemost 2003;29(2):125–130.
460 | PVRI statement on pregnancy in PH Hemnes et al.
92. Capeless EL, Clapp JF. When do cardiovascular parameters return to
their preconception values? Am J Obstetr Gynecol 1991;165(4):883–886.
93. Fuchs KI, Moore LG, Rounds S. Pulmonary vascular reactivity is
blunted in pregnant rats. J Appl Physiol 1982;53(3):703–707.
94. Moore LG, Reeves JT. Pregnancy blunts pulmonary vascular reactiv-
ity in dogs. Am J Physiol Heart Circ Physiol 1980;239(3):H297–H301.
95. Argiento P, Vanderpool RR, Mulè M, Russo MG, D’Alto M, Bossone
E, Chesler NC, Naeije R. Exercise stress echocardiography of the
pulmonary circulation: limits of normal and sex differences. Chest
2012;142(5):1158–1165.
96. Lahm T, Crisostomo PR, Markel TA, Wang M, Wang Y, Tan J,
Meldrum DR. Selective estrogen receptor-α and estrogen receptor-β
agonists rapidly decrease pulmonary artery vasoconstriction by a nitric
oxide-dependent mechanism. Am J Physiol Regul Integr Comp Physiol
2008;295(5):R1486–R1493.
97. Lahm T, Crisostomo PR, Markel TA, Wang M, Wang Y, Weil B,
Meldrum DR. Exogenous estrogen rapidly attenuates pulmonary ar-
tery vasoreactivity and acute hypoxic pulmonary vasoconstriction.
Shock 2008;30(6):660–667.
98. Jones RD, English KM, Pugh PJ, Morice AH, Jones TH, Channer KS.
Pulmonary vasodilatory action of testosterone: evidence of a calcium
antagonistic action. J Cardiovasc Pharmacol 2002;39(6):814–823.
99. English KM, Jones RD, Jones TH, Morice AH, Channer KS. Gender
differences in the vasomotor effects of different steroid hormones in
rat pulmonary and coronary arteries. Horm Metab Res 2001;33(11):
645–652.
100. Lahm T, Patel KM, Crisostomo PR, Markel TA, Wang M, Herring C,
Meldrum DR. Endogenous estrogen attenuates pulmonary artery vaso-
reactivity and acute hypoxic pulmonary vasoconstriction: the effects of
sex and menstrual cycle. Am J Physiol Endocrinol Metab 2007; 293(3):
E865–E871.
101. Chambliss KL, Yuhanna IS, Anderson RG, Mendelsohn ME, Shaul
PW. ERβ has nongenomic action in caveolae. Mol Endocrinol 2002;
16 (5):938–946.
102. Hisamoto K, Ohmichi M, Kurachi H, Hayakawa J, Kanda Y, Nishio
Y, Adachi K, et al. Estrogen induces the Akt-dependent activation of
endothelial nitric-oxide synthase in vascular endothelial cells. J Biol
Chem 2001;276(5):3459–3467.
103. Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn
ME, Shaul PW. Estrogen receptor α mediates the nongenomic activa-
tion of endothelial nitric oxide synthase by estrogen. J Clin Invest
1999;103(3):401–406.
104. Sherman TS, Chambliss KL, Gibson LL, Pace MC, Mendelsohn ME,
Pﬁster SL, Shaul PW. Estrogen acutely activates prostacyclin synthe-
sis in ovine fetal pulmonary artery endothelium. Am J Respir Cell
Mol Biol 2002;26(5):610–616.
105. Earley S, Resta TC. Estradiol attenuates hypoxia-induced pulmonary
endothelin-1 gene expression. Am J Physiol Lung Cell Mol Physiol
2002;283(1):L86–L93.
106. Yuan P, Wu WH, Gao L, Zheng ZQ, Liu D, Mei HY, Zhang ZL, Jing
ZC. Oestradiol ameliorates monocrotaline pulmonary hypertension
via NO, prostacyclin and endothelin-1 pathways. Eur Respir J 2013;
41(5):1116–1125.
107. Barberis MC, Veronese S, Bauer D, De Juli E, Harari S. Immunocyto-
chemical detection of progesterone receptors. A study in a patient
with primary pulmonary hypertension. Chest 1995;107(3):869–872.
108. Tofovic SP. Estrogens and development of pulmonary hypertension:
interaction of estradiol metabolism and pulmonary vascular disease. J
Cardiovasc Pharmacol 2010;56(6):696–708.
109. Kawut SM, Al-Naamani N, Agerstrand C, Rosenzweig EB, Rowan C,
Barst RJ, Bergmann S, Horn EM. Determinants of right ventricular ejec-
tion fraction in pulmonary arterial hypertension. Chest 2009;135(3):
752–759.
110. Ventetuolo CE, Ouyang P, Bluemke DA, Tandri H, Barr RG, Bagiella
E, Cappola AR, et al. Sex hormones are associated with right ventric-
ular structure and function: the MESA-Right Ventricle Study. Am J
Respir Crit Care Med 2011;183(5):659–667.
111. Ventetuolo CE, Praestgaard A, Palevsky HI, Klinger JR, Halpern SD,
Kawut SM. Sex and haemodynamics in pulmonary arterial hyperten-
sion. Eur Respir J 2014;43(2):523–530.
112. Umar S, Iorga A, Matori H, Nadadur RD, Li J, Maltese F, van der
Laarse A, Eghbali M. Estrogen rescues preexisting severe pulmonary
hypertension in rats. Am J Respir Crit Care Med 2011;184(6):715–723.
113. Farha S, Asosingh K, Laskowski D, Licina L, Sekigushi H, Losordo
DW, Dweik RA, Wiedemann HP, Erzurum SC. Pulmonary gas trans-
fer related to markers of angiogenesis during the menstrual cycle. J
Appl Physiol 2007;103(5):1789–1795.
114. Pare G, Krust A, Karas RH, Dupont S, Aronovitz M, Chambon P,
Mendelsohn ME. Estrogen receptor-α mediates the protective effects
of estrogen against vascular injury. Circ Res 2002;90(10):1087–1092.
115. Lahm T, Albrecht M, Fisher AJ, Selej M, Patel NG, Brown JA, Justice
MJ, et al. 17β-estradiol attenuates hypoxic pulmonary hypertension
via estrogen receptor-mediated effects. Am J Respir Crit Care Med
2012;185(9):965–980.
116. Xu DQ, Luo Y, Liu Y, Wang J, Zhang B, Xu M, Wang YX, et al.
Beta-estradiol attenuates hypoxic pulmonary hypertension by stabi-
lizing the expression of p27kip1 in rats. Respir Res 2010;11:182.
117. Dubey RK, Jackson EK, Keller PJ, Imthurn B, Rosselli M. Estradiol
metabolites inhibit endothelin synthesis by an estrogen receptor-
independent mechanism. Hypertension 2001;37(2):640–644.
118. Dubey RK, Tofovic SP, Jackson EK. Cardiovascular pharmacology of
estradiol metabolites. J Pharmacol Exp Ther 2004;308(2):403–409.
119. Dubey RK, Tyurina YY, Tyurin VA, Gillespie DG, Branch RA,
Jackson EK, Kagan VE. Estrogen and tamoxifen metabolites protect
smooth muscle cell membrane phospholipids against peroxidation
and inhibit cell growth. Circ Res 1999;84(2):229–239.
120. Zacharia LC, Gogos JA, Karayiorgou M, Jackson EK, Gillespie DG,
Barchiesi F, Dubey RK. Methoxyestradiols mediate the antimitogenic ef-
fects of 17β-estradiol: direct evidence from catechol-O-methyltransferase-
knockout mice. Circulation 2003;108(24):2974–2978.
121. Farrukh IS, Peng W, Orlinska U, Hoidal JR. Effect of dehydroepi-
androsterone on hypoxic pulmonary vasoconstriction: a Ca2+-activated
K+-channel opener. Am J Physiol Lung Cell Mol Physiol 1998;274(2):
L186–L195.
122. Bonnet S, Dumas-de La Roque E, Bégueret H, Marthan R, Fayon M,
Dos Santos P, Savineau JP, Baulieu EE. Dehydroepiandrosterone
(DHEA) prevents and reverses chronic hypoxic pulmonary hyperten-
sion. Proc Natl Acad Sci USA 2003;100(16):9488–9493.
123. Hampl V, Bíbová J, Povýšilová V, Herget J. Dehydroepiandrosterone
sulphate reduces chronic hypoxic pulmonary hypertension in rats.
Eur Respir J 2003;21(5):862–865.
124. Homma N, Nagaoka T, Karoor V, Imamura M, Taraseviciene-
Stewart L, Walker LA, Fagan KA, McMurtry IF, Oka M. Involvement
of RhoA/Rho kinase signaling in protection against monocrotaline-
induced pulmonary hypertension in pneumonectomized rats by dehy-
droepiandrosterone. Am J Physiol Lung Cell Mol Physiol 2008;295(1):
L71–L78.
125. Oka M, Karoor V, Homma N, Nagaoka T, Sakao E, Golembeski SM,
Limbird J, et al. Dehydroepiandrosterone upregulates soluble guanylate
cyclase and inhibits hypoxic pulmonary hypertension. Cardiovasc Res
2007;74(3):377–387.
126. Paulin R, Meloche J, Jacob MH, Bisserier M, Courboulin A, Bonnet
S. Dehydroepiandrosterone inhibits the Src/STAT3 constitutive acti-
vation in pulmonary arterial hypertension. Am J Physiol Heart Circ
Physiol 2011;301(5):H1798–H1809.
127. Jelinic M, Leo CH, Post Uiterweer ED, Gooi JH, Wlodek ME,
Conrad KP, Parkington H, Tare M, Parry LJ. Localization of relaxin
receptors in arteries and veins, and region-speciﬁc increases in com-
pliance and bradykinin-mediated relaxation after in vivo serelaxin treat-
ment. FASEB J 2014;28(1):275–287.
Pulmonary Circulation Volume 5 Number 3 September 2015 | 461
128. Dschietzig T, Richter C, Bartsch C, Böhme C, Heinze D, Ott F,
Zartnack F, Baumann G, Stangl K. Flow-induced pressure differen-
tially regulates endothelin-1, urotensin II, adrenomedullin, and relaxin
in pulmonary vascular endothelium. Biochem Biophys Res Commun
2001;289(1):245–251.
129. Tozzi CA, Poiani GJ, McHugh NA, Sharkarjian MP, Grove BH, Sam-
uel CS, Unemori EN, Riley DJ. Recombinant human relaxin reduces
hypoxic pulmonary hypertension in the rat. Pulm Pharmacol Ther
2005;18(5):346–353.
130. Hönicke U, Albrecht S, Schrötter H, Krug S, Kolditz M, Kuhlisch E,
Höffken G, Halank M. Prolactin and its 16-kDa N-terminal frag-
ment: are higher in patients with precapillary pulmonary hypertension
than in a healthy control group. Tex Heart Inst J 2012;39(1):44–50.
131. Sokolova J, Zimmermann R, Kreuder J, Michel-Behnke I, Schranz D,
Piper HM, Schlüter K-D. Impaired release of bioactive parathyroid
hormone-related peptide in patients with pulmonary hypertension
and endothelial dysfunction. J Vasc Res 2007;44(1):67–74.
132. Maron BA, Opotowsky AR, Landzberg MJ, Loscalzo J, Waxman AB,
Leopold JA. Plasma aldosterone levels are elevated in patients with
pulmonary arterial hypertension in the absence of left ventricular
heart failure: a pilot study. Eur J Heart Fail 2013;15(3):277–283.
133. Hernández-Díaz S, Van Marter LJ, Werler MM, Louik C, Mitchell
AA. Risk factors for persistent pulmonary hypertension of the new-
born. Pediatrics 2007;120(2):e272–e282.
134. Dempsie Y, MacRitchie NA, White K, Morecroft I, Wright AF,
Nilsen M, Loughlin L, Mair KM, MacLean MR. Dexfenﬂuramine
and the oestrogen-metabolizing enzyme CYP1B1 in the development
of pulmonary arterial hypertension. Cardiovasc Res 2013;99(1):24–
34.
135. Dempsie Y, Nilsen M, White K, Mair KM, Loughlin L, Ambartsumian
N, Rabinovitch M, MacLean MR. Development of pulmonary arterial
hypertension in mice over-expressing S100A4/Mts1 is speciﬁc to fe-
males. Respir Res 2011;12:159.
136. White K, Dempsie Y, Nilsen M, Wright AF, Loughlin L, Maclean
MR. The serotonin transporter, gender, and 17β oestradiol in the de-
velopment of pulmonary arterial hypertension. Cardiovasc Res 2011;
90(2):373–382.
137. White K, Loughlin L, Maqbool Z, Nilsen M, McClure J, Dempsie Y,
Baker AH, MacLean MR. Serotonin transporter, sex, and hypoxia:
microarray analysis in the pulmonary arteries of mice identiﬁes genes
with relevance to human PAH. Physiol Genomics 2011;43(8):417–
437.
138. Simpson ER, Clyne C, Rubin G, Boon WC, Robertson K, Britt K,
Speed C, Jones M. Aromatase—a brief overview. Annu Rev Physiol
2002;64:93–127.
139. Mair KM, Wright AF, Duggan N, Rowlands DJ, Hussey MJ, Roberts
S, Fullerton J, et al. Sex-dependent inﬂuence of endogenous estrogen
in pulmonary hypertension. Am J Respir Crit Care Med 2014;190(4):
456–467.
140. White K, Johansen AK, Nilsen M, Ciuclan L, Wallace E, Paton L,
Campbell A, et al. Activity of the estrogen-metabolizing enzyme cy-
tochrome P450 1B1 inﬂuences the development of pulmonary arte-
rial hypertension. Circulation 2012;126(9):1087–1098.
141. Yang X, Long L, Southwood M, Rudarakanchana N, Upton PD,
Jeffery TK, Atkinson C, Chen H, Trembath RC, Morrell NW. Dys-
functional Smad signaling contributes to abnormal smooth muscle
cell proliferation in familial pulmonary arterial hypertension. Circ
Res 2005;96(10):1053–1063.
142. Austin ED, Cogan JD, West JD, Hedges LK, Hamid R, Dawson EP,
Wheeler LA, Parl FF, Loyd JE, Phillips JA III. Alterations in oestro-
gen metabolism: implications for higher penetrance of familial pulmo-
nary arterial hypertension in females. Eur Respir J 2009;34(5): 1093–
1099.
143. Isoherranen N, Thummel KE. Drug metabolism and transport during
pregnancy: how does drug disposition change during pregnancy and
what are the mechanisms that cause such changes? Drug Metab Dispos
2013;41(2):256–262.
144. Roberts KE, Fallon MB, Krowka MJ, Brown RS, Trotter JF, Peter I,
Tighiouart H, et al. Genetic risk factors for portopulmonary hyper-
tension in patients with advanced liver disease. Am J Respir Crit Care
Med 2009;179(9):835–842.
145. Greenstein D, Jeffcote N, Ilsley D, Kester RC. The menstrual cycle
and Raynaud’s phenomenon. Angiology 1996;47(5):427–436.
146. MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Incidence of
migraine relative to menstrual cycle phases of rising and falling estro-
gen. Neurology 2006;67(12):2154–2158.
147. Rosano GM, Collins P, Kaski JC, Lindsay DC, Sarrel PM, Poole-
Wilson PA. Syndrome X in women is associated with oestrogen deﬁ-
ciency. Eur Heart J 1995;16(5):610–614.
148. Eghbali M, Deva R, Alioua A, Minosyan TY, Ruan H, Wang Y, Toro
L, Stefani E. Molecular and functional signature of heart hypertrophy
during pregnancy. Circ Res 2005;96(11):1208–1216.
149. Pluim BM, Zwinderman AH, van der Laarse A, van der Wall EE.
The athlete’s heart: a meta-analysis of cardiac structure and function.
Circulation 2000;101(3):336–344.
150. Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD,
Meldrum DR, Dupuis J, et al. Right ventricular function and failure:
report of a National Heart, Lung, and Blood Institute working group
on cellular and molecular mechanisms of right heart failure. Circula-
tion 2006;114(17):1883–1891.
151. Haddad F, Hunt SA, Rosenthal DN, Murphy DJ. Right ventricular func-
tion in cardiovascular disease, part I: anatomy, physiology, aging, and
functional assessment of the right ventricle. Circulation 2008;117(11):
1436–1448.
152. Li J, Umar S, Amjedi M, Iorga A, Sharma S, Nadadur RD, Regitz-
Zagrosek V, Eghbali M. New frontiers in heart hypertrophy during
pregnancy. Am J Cardiovasc Dis 2012;2(3):192–207.
153. Bogaard HJ, Natarajan R, Henderson SC, Long CS, Kraskauskas D,
Smithson L, Ockaili R, McCord JM, Voelkel NF. Chronic pulmonary
artery pressure elevation is insufﬁcient to explain right heart failure.
Circulation 2009;120(20):1951–1960.
154. Drake JI, Bogaard HJ, Mizuno S, Clifton B, Xie B, Gao Y, Dumur CI,
Fawcett P, Voelkel NF, Natarajan R. Molecular signature of a right
heart failure program in chronic severe pulmonary hypertension. Am
J Respir Cell Mol Biol 2011;45(6):1239–1247.
155. Umar S, Nadadur R, Iorga A, Amjedi M, Matori H, Eghbali M.
Cardiac structural and hemodynamic changes associated with physio-
logical heart hypertrophy of pregnancy are reversed postpartum. J
Appl Physiol 2012;113(8):1253–1259.
156. Iorga A, Dewey S, Partow-Navid R, Gomes AV, Eghbali M. Pregnancy
is associated with decreased cardiac proteasome activity and oxida-
tive stress in mice. PLoS ONE 2012;7:e48601. doi:10.1371/journal.pone
.0048601.
157. Brower GL, Gardner JD, Janicki JS. Gender mediated cardiac protec-
tion from adverse ventricular remodeling is abolished by ovariectomy.
Mol Cell Biochem 2003;251(1):89–95.
158. Fliegner D, Schubert C, Penkalla A, Witt H, Kararigas G, Dworatzek
E, Staub E, et al. Female sex and estrogen receptor-β attenuate car-
diac remodeling and apoptosis in pressure overload. Am J Physiol
Regul Integr Comp Physiol 2010;298(6):R1597–R1606.
159. Gardner JD, Brower GL, Janicki JS. Gender differences in cardiac
remodeling secondary to chronic volume overload. J Card Failure 2002;
8(2):101–107.
160. Gardner JD, Brower GL, Voloshenyuk TG, Janicki JS. Cardio-
protection in female rats subjected to chronic volume overload: syner-
gistic interaction of estrogen and phytoestrogens. Am J Physiol Heart
Circ Physiol 2008;294(1):H198–H204.
161. Lin J, Steenbergen C, Murphy E, Sun J. Estrogen receptor-β activa-
tion results in S-nitrosylation of proteins involved in cardioprotection.
Circulation 2009;120(3):245–254.
462 | PVRI statement on pregnancy in PH Hemnes et al.
162. Wang M, Crisostomo P, Wairiuko GM, Meldrum DR. Estrogen
receptor-α mediates acute myocardial protection in females. Am J
Physiol Heart Circ Physiol 2006;290(5):H2204–H2209.
163. Wang M, Wang Y, Weil B, Abarbanell A, Herrmann J, Tan J, Kelly
M, Meldrum DR. Estrogen receptor β mediates increased activation
of PI3K/Akt signaling and improved myocardial function in female
hearts following acute ischemia. Am J Physiol Regul Integr Comp
Physiol 2009;296(4):R972–R978.
164. Kararigas G, Fliegner D, Gustafsson JÅ, Regitz-Zagrosek V. Role of
the estrogen/estrogen-receptor-beta axis in the genomic response to
pressure overload-induced hypertrophy. Physiol Genomics 2011;43(8):
438–446.
165. Queirós AM, Eschen C, Fliegner D, Kararigas G, Dworatzek E,
Westphal C, Sanchez Ruderisch H, Regitz-Zagrosek V. Sex- and estrogen-
dependent regulation of a miRNA network in the healthy and hyper-
trophied heart. Int J Cardiol 2013;169(5):331–338.
166. Pedram A, Razandi M, O’Mahony F, Lubahn D, Levin ER. Estrogen
receptor-β prevents cardiac ﬁbrosis. Mol Endocrinol 2010;24(11):
2152–2165.
167. Murphy E. Estrogen signaling and cardiovascular disease. Circ Res
2011;109(6):687–696.
168. Pedram A, Razandi M, Aitkenhead M, Levin ER. Estrogen inhibits
cardiomyocyte hypertrophy in vitro: antagonism of calcineurin-related
hypertrophy through induction of MCIP1. J Biol Chem 2005;280(28):
26339–26348.
169. Babiker FA, De Windt LJ, van Eickels M, Thijssen V, Bronsaer RJP,
Grohé C, van Bilsen M, Doevendans PA. 17β-estradiol antagonizes
cardiomyocyte hypertrophy by autocrine/paracrine stimulation of a
guanylyl cyclase A receptor-cyclic guanosine monophosphate-dependent
protein kinase pathway. Circulation 2004;109(2):269–276.
170. Westphal C, Schubert C, Prelle K, Penkalla A, Fliegner D, Petrov G,
Regitz-Zagrosek V. Effects of estrogen, an ERα agonist and raloxifene
on pressure overload induced cardiac hypertrophy. PLoS ONE 2012;
7:e50802. doi:10.1371/journal.pone.0050802.
171. Kawut SM, Lima JA, Barr RG, Chahal H, Jain A, Tandri H,
Praestgaard A, et al. Sex and race differences in right ventricular
structure and function: the Multi-Ethnic Study of Atherosclerosis–
Right Ventricle Study. Circulation 2011;123(22):2542–2551.
172. Nadadur RD, Umar S, Wong G, Eghbali M, Iorga A, Matori H,
Partow-Navid R, Eghbali M. Reverse right ventricular structural and
extracellular matrix remodeling by estrogen in severe pulmonary hy-
pertension. J Appl Physiol 2012;113(1):149–158.
173. Alzoubi A, Toba M, Abe K, O’Neill KD, Rocic P, Fagan KA,
McMurtry IF, Oka M. Dehydroepiandrosterone restores right ventricu-
lar structure and function in rats with severe pulmonary arterial hyper-
tension. Am J Physiol Heart Circ Physiol 2013;304(12):H1708–H1718.
174. Dumas-de La Roque E, Bellance N, Rossignol R, Begueret H, Billaud
M, Dos Santos P, Ducret T, et al. Dehydroepiandrosterone reverses
chronic hypoxia/reoxygenation-induced right ventricular dysfunction
in rats. Eur Respir J 2012;40(6):1420–1429.
175. Hemnes AR, Maynard KB, Champion HC, Gleaves L, Penner N,
West J, Newman JH. Testosterone negatively regulates right ventricu-
lar load stress responses in mice. Pulm Circ 2012;2(3):352–358.
176. Klinga K, Bek E, Runnebaum B. Maternal peripheral testosterone
levels during the ﬁrst half of pregnancy. Am J Obstetr Gynecol 1978;
131(1):60–62.
177. Bammann BL, Coulam CB, Jiang NS. Total and free testosterone
during pregnancy. Am J Obstetr Gynecol 1980;137(3):293–298.
178. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM,
Louik C, Jones KL, Mitchell AA. Selective serotonin-reuptake inhibi-
tors and risk of persistent pulmonary hypertension of the newborn.
N Engl J Med 2006;354(6):579–587.
179. Galbally M, Gentile S, Lewis AJ. Further ﬁndings linking SSRIs dur-
ing pregnancy and persistent pulmonary hypertension of the new-
born: clinical implications. CNS Drugs 2012;26(10):813–822.
180. Källén B, Olausson PO. Maternal use of selective serotonin re-uptake
inhibitors and persistent pulmonary hypertension of the newborn.
Pharmacoepidemiol Drug Saf 2008;17(8):801–806.
181. ’t Jong GW, Einarson T, Koren G, Einarson A. Antidepressant use in
pregnancy and persistent pulmonary hypertension of the newborn
(PPHN): a systematic review. Reprod Toxicol 2012;34(3):293–297.
182. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C.
Effects of timing and duration of gestational exposure to serotonin
reuptake inhibitor antidepressants: population-based study. Br J Psy-
chiatry 2008;192(5):338–343.
183. Hilli J, Heikkinen T, Rontu R, Lehtimäki T, Kishida I, Aklillu E,
Bertilsson L, Vahlberg T, Laine K. MAO-A and COMT genotypes as
possible regulators of perinatal serotonergic symptoms after in utero
exposure to SSRIs. Eur Neuropsychopharmacol 2009;19(5):363–370.
184. Ellfolk M, Malm H. Risks associated with in utero and lactation
exposure to selective serotonin reuptake inhibitors (SSRIs). Reprod
Toxicol 2010;30(2):249–260.
185. Delaney C, Gien J, Grover TR, Roe G, Abman SH. Pulmonary vascu-
lar effects of serotonin and selective serotonin reuptake inhibitors in
the late-gestation ovine fetus. Am J Physiol Lung Cell Mol Physiol
2011;301(6):L937–L944.
186. Delaney C, Gien J, Roe G, Isenberg N, Kailey J, Abman SH. Seroto-
nin contributes to high pulmonary vascular tone in a sheep model of
persistent pulmonary hypertension of the newborn. Am J Physiol
Lung Cell Mol Physiol 2013;304(12):L894–L901.
187. Grigoriadis S, VonderPorten EH, Mamisashvili L, Tomlinson G,
Dennis C-L, Koren G, Steiner M, Mousmanis P, Cheung A, Ross LE.
Prenatal exposure to antidepressants and persistent pulmonary hy-
pertension of the newborn: systematic review and meta-analysis. BMJ
2014;348:f6932. doi:10.1136/bmj.f6932.
188. D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH,
Detre KM, Fishman AP, et al. Survival in patients with primary pul-
monary hypertension: results from a national prospective registry.
Ann Intern Med 1991;115(5):343–349.
189. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD.
An evaluation of long-term survival from time of diagnosis in pul-
monary arterial hypertension from the REVEAL Registry. Chest 2012;
142(2):448–456.
190. Humbert M, Sitbon O, Yaïci A, Montani D, O’Callaghan DS, Jaïs X,
Parent F, et al. Survival in incident and prevalent cohorts of patients
with pulmonary arterial hypertension. Eur Respir J 2010;36(3):549–
555.
191. Ling Y, Johnson MK, Kiely DG, Condliffe R, Elliot CA, Gibbs JS,
Howard LS, et al. Changing demographics, epidemiology, and sur-
vival of incident pulmonary arterial hypertension: results from the
pulmonary hypertension registry of the United Kingdom and Ireland.
Am J Respir Crit Care Med 2012;186(8):790–796.
192. Katsuragi S, Yamanaka K, Neki R, Kamiya C, Sasaki Y, Osato K,
Miyoshi T, et al. Maternal outcome in pregnancy complicated with
pulmonary arterial hypertension. Circ J 2012;76(9):2249–2254.
193. Curry RA, Fletcher C, Gelson E, Gatzoulis MA, Woolnough M,
Richards N, Swan L, Steer PJ, Johnson MR. Pulmonary hypertension
and pregnancy—a review of 12 pregnancies in nine women. BJOG
2012;119(6):752–761.
194. Duarte AG, Thomas S, Safdar Z, Torres F, Pacheco LD, Feldman J,
deBoisblanc B. Management of pulmonary arterial hypertension dur-
ing pregnancy: a retrospective, multicenter experience. Chest 2013;
143(5):1330–1336.
195. Kiely DG, Condliffe R, Webster V, Mills GH, Wrench I, Gandhi
SV, Selby K, et al. Improved survival in pregnancy and pulmonary
hypertension using a multiprofessional approach. BJOG 2010;117(5):
565–574.
196. Monnery L, Nanson J, Charlton G. Primary pulmonary hypertension
in pregnancy; a role for novel vasodilators. Br J Anaesth 2001;87(2):
295–298.
Pulmonary Circulation Volume 5 Number 3 September 2015 | 463
197. Bendayan D, Hod M, Oron G, Sagie A, Eidelman L, Shitrit D, Kramer
MR. Pregnancy outcome in patients with pulmonary arterial hyper-
tension receiving prostacyclin therapy. Obstetr Gynecol 2005;106(5):
1206–1210.
198. Elliot CA, Stewart P, Webster VJ, Mills GH, Hutchinson SP,
Howarth ES, Bu’Lock FA, Lawson RA, Armstrong IJ, Kiely DG. The
use of iloprost in early pregnancy in patients with pulmonary arterial
hypertension. Eur Respir J 2005;26(1):168–173.
199. Bédard E, McCarthy KP, Dimopoulos K, Giannakoulas G, Gatzoulis
MA, Ho SY. Structural abnormalities of the pulmonary trunk in te-
tralogy of Fallot and potential clinical implications: a morphological
study. J Am Coll Cardiol 2009;54(20):1883–1890.
200. Ma L, Liu W, Huang Y. Perioperative management for parturients
with pulmonary hypertension: experience with 30 consecutive cases.
Front Med 2012;6(3):307–310.
201. Cotrim SC, Loureiro MJ, Avillez T, Simões O, Cordeiro P, Almeida S,
Miranda R, Almeida AR, Carrageta M. Three cases of pregnancy in
patients with severe pulmonary arterial hypertension: experience of a
single unit. Rev Port Cardiol 2010;29(1):95–103.
202. Rosengarten D, Blieden LC, Kramer MR. Pregnancy outcomes in
pulmonary arterial hypertension in the modern management era. Eur
Respir J 2012;40(5):1304–1305.
203. Kovacs AH, Harrison JL, Colman JM, Sermer M, Siu SC, Silversides
CK. Pregnancy and contraception in congenital heart disease: what
women are not told. J Am Coll Cardiol 2008;52(7):577–578.
204. Vigl M, Kaemmerer M, Seifert-Klauss V, Niggemeyer E, Nagdyman
N, Trigas V, Bauer U, et al. Contraception in women with congenital
heart disease. Am J Cardiol 2010;106(9):1317–1321.
205. Trussell J. Contraceptive failure in the United States. Contraception
2011;83(5):397–404.
206. Poulter NR, Chang CL, Farley TMM, Marmot MG, Meirik O. Car-
diovascular disease and use of oral and injectable progestogen-only
contraceptives and combined injectable contraceptives: results of an
international, multicenter, case-control study. World Health Organi-
zation Collaborative Study of Cardiovascular Disease and Steroid
Hormone Contraception. Contraception 1998;57(5):315–324.
207. van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR. The risk of deep
venous thrombosis associated with injectable depot-medroxyprogesterone
acetate contraceptives or a levonorgestrel intrauterine device. Arterio
Thromb Vasc Biol 2010;30(11):2297–2300.
208. Mantha S, Karp R, Raghavan V, Terrin N, Bauer KA, Zwicker JI.
Assessing the risk of venous thromboembolic events in women taking
progestin-only contraception: a meta-analysis. BMJ 2012;345:e4944.
doi:10.1136/bmj.e4944.
209. Nanda K, Amaral E, Hays M, Viscola MA, Mehta N, Bahamondes L.
Pharmacokinetic interactions between depot medroxyprogesterone ace-
tate and combination antiretroviral therapy. Fertil Sterility 2008;90(4):
965–971.
210. Nilsson CG, Lähteenmäki P, Robertson DN, Luukkainen T. Plasma
concentrations of levonorgestrel as a function of the release rate of
levonorgestrel from medicated intra-uterine devices. Acta Endocrinol
1980;93(3):380–384.
211. Croxatto HB, Mäkäräinen L. The pharmacodynamics and efﬁcacy of
Implanon: an overview of the data. Contraception 1998;58(suppl. 2):
91S–97S.
212. Huber J. Pharmacokinetics of Implanon: an integrated analysis. Con-
traception 1998;58(suppl. 2):85S–90S.
213. Hatcher RA, Trussell J, Nelson AL, Cates W Jr., Kowal D, Policar M.
Contraceptive technology. 20th rev. ed. New York: Ardent Media, 2011.
214. Raymond EG, Trussell J, Weaver MA, Reeves MF. Estimating contra-
ceptive efﬁcacy: the case of spermicides. Contraception 2013;87(2):
134–137.
215. Famuyide AO, Hopkins MR, El-Nashar SA, Creedon DJ, Vasdev
GM, Driscoll DJ, Connolly HM, Warnes CA. Hysteroscopic steriliza-
tion in women with severe cardiac disease: experience at a tertiary
center. Mayo Clin Proc 2008;83(4):431–438.
216. Hemnes AR, Robbins IM. Hysteroscopic sterilization in women with
pulmonary vascular disease. Mayo Clin Proc 2008;83(10):1188–1189;
reply 1189.
217. Cleland K, Zhu H, Goldstuck N, Cheng L, Trussell J. The efﬁcacy of
intrauterine devices for emergency contraception: a systematic review
of 35 years of experience. Hum Reprod 2012;27(7):1994–2000.
218. Austin ED, Loyd JE. Heritable forms of pulmonary arterial hyperten-
sion. Semin Respir Crit Care Med 2013;34(5):568–580.
219. Soubrier F, Chung WK, Machado R, Grünig E, Aldred M, Geraci M,
Loyd JE, et al. Genetics and genomics of pulmonary arterial hyper-
tension. J Am Coll Cardiol 2013;62(25 suppl.):D13–D21.
220. Austin ED, Ma L, LeDuc C, Berman Rosenzweig E, Borczuk A, Phil-
lips JA III, Palomero T, et al. Whole exome sequencing to identify a
novel gene (caveolin-1) associated with human pulmonary arterial
hypertension. Circ Cardiovasc Genet 2012;5(3):336–343.
221. Ma L, Roman-Campos D, Austin ED, Eyries M, Sampson KS,
Soubrier F, Germain M, et al. A novel channelopathy in pulmonary
arterial hypertension. N Engl J Med 2013;369(4):351–361.
222. Best DH, Sumner KL, Austin ED, Chung WK, Brown LM, Borczuk
AC, Rosenzweig EB, et al. EIF2AK4 mutations in pulmonary capillary
hemangiomatosis. Chest 2014;145(2):231–236.
223. Koehler R, Grünig E, Pauciulo MW, Hoeper MM, Olschewski H,
Wilkens H, Halank M, et al. Low frequency of BMPR2 mutations in
a German cohort of patients with sporadic idiopathic pulmonary
arterial hypertension. J Med Genet 2004;41(12):e127.
224. Regitz-Zagrosek V, Lundqvist CB, Borghi C, Cifkova R, Ferreira R,
Foidart JM, Gibbs JSR, et al. ESC guidelines on the management of
cardiovascular diseases during pregnancy: the Task Force on the Man-
agement of Cardiovascular Diseases during Pregnancy of the European
Society of Cardiology (ESC). Eur Heart J 2011;32(24): 3147–3197.
225. Pieper PG, Hoendermis ES. Pregnancy in women with pulmonary
hypertension. Neth Heart J 2011;19(12):504–508.
226. Wexler ID, Johannesson M, Edenborough FP, Suﬁan BS, Kerem E.
Pregnancy and chronic progressive pulmonary disease. Am J Respir
Crit Care Med 2007;175(4):300–305.
227. Jain JK, Mishell DR Jr. A comparison of intravaginal misoprostol
with prostaglandin E2 for termination of second-trimester pregnancy.
N Engl J Med 1994;331(5):290–293.
228. Easterling TR, Ralph DD, Schmucker BC. Pulmonary hypertension in
pregnancy: treatment with pulmonary vasodilators. Obstetr Gynecol
1999;93(4):494–498.
229. Liu S, Liston RM, Joseph KS, Heaman M, Sauve R, Kramer MS.
Maternal mortality and severe morbidity associated with low-risk
planned cesarean delivery versus planned vaginal delivery at term.
Can Med Assoc J 2007;176(4):455–460.
230. Heerdt PM, Caldwell RW. The mechanism of nitrous oxide-induced
changes in pulmonary vascular resistance in a dog model of left atrial
outﬂow obstruction. J Cardiothorac Anesth 1989;3(5):568–573.
231. Sørensen MB, Jacobsen E. Pulmonary hemodynamics during induc-
tion of anesthesia. Anesthesiology 1977;46(4):246–251.
232. Hoeper MM, Granton J. Intensive care unit management of patients
with severe pulmonary hypertension and right heart failure. Am J
Respir Crit Care Med 2011;184(10):1114–1124.
233. Duggan AB, Katz SG. Combined spinal and epidural anaesthesia for
caesarean section in a parturient with severe primary pulmonary hy-
pertension. Anaesth Intensive Care 2003;31(5):565–569.
234. Smedstad KG, Cramb R, Morison DH. Pulmonary hypertension and
pregnancy: a series of eight cases. Can J Anaesth 1994;41(6): 502–512.
235. Le RJ, Fenstad ER, Maradit-Kremers H, McCully RB, Frantz RP,
McGoon MD, Kane GC. Syncope in adults with pulmonary arterial
hypertension [retracted in J Am Coll Cardiol 59(21):1919]. J Am Coll
Cardiol 2011;58(8):863–867.
464 | PVRI statement on pregnancy in PH Hemnes et al.
236. Brignole M, Alboni P, Benditt DG, Bergfeldt L, Blanc JJ, Bloch
Thomsen PE, van Dijk JG, et al. Guidelines on management (diagno-
sis and treatment) of syncope—update 2004: executive summary. Eur
Heart J 2004;25(22):2054–2072.
237. Yarlagadda S, Poma PA, Green LS, Katz V. Syncope during preg-
nancy. Obstetr Gynecol 2010;115(2):377–380.
238. Brittain EL, Pugh ME, Wheeler LA, Robbins IM, Loyd JE, Newman
JH, Austin ED, Hemnes AR. Prostanoids but not oral therapies im-
prove right ventricular function in pulmonary arterial hypertension.
JACC Heart Failure 2013;1(4):300–307.
239. Waxman AB, Zamanian RT. Pulmonary arterial hypertension: new
insights into the optimal role of current and emerging prostacyclin
therapies. Am J Cardiol 2013;111(5 suppl.):1A–16A; quiz 17A–19A.
240. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW,
Lindner JR, Mathier MA, et al. ACCF/AHA 2009 expert consensus doc-
ument on pulmonary hypertension: a report of the American College
of Cardiology Foundation Task Force on Expert Consensus Documents
and the American Heart Association: developed in collaboration with
the American College of Chest Physicians; American Thoracic Society,
Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol
2009;53(17):1573–1619.
241. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiéry JL, Barberà
JA, Beghetti M, et al. Guidelines for the diagnosis and treatment of
pulmonary hypertension. Eur Respir J 2009;34(6):1219–1263.
242. Hsu CH, Gomberg-Maitland M, Glassner C, Chen JH. The manage-
ment of pregnancy and pregnancy-related medical conditions in pul-
monary arterial hypertension patients. Int J Clin Pract Suppl 2011;65
(suppl. s172):6–14.
243. Decoene C, Bourzouﬁ K, Moreau D, Narducci F, Crepin F, Krivosic-
Horber R. Use of inhaled nitric oxide for emergency cesarean section
in a woman with unexpected primary pulmonary hypertension. Can
J Anaesth 2001;48(6):584–587.
244. Goland S, Tsai F, Habib M, Janmohamed M, Goodwin TM, Elkayam
U. Favorable outcome of pregnancy with an elective use of epopros-
tenol and sildenaﬁl in women with severe pulmonary hypertension.
Cardiology 2010;115(3):205–208.
245. Taçoy G, Ekim NN, Çengel A. Dramatic response of a patient with
pregnancy induced idiopathic pulmonary arterial hypertension to
sildenaﬁl treatment. J Obstetr Gynaecol Res 2010;36(2):414–417.
246. Sitbon O, Humbert M, Jaïs X, Ioos V, Hamid AM, Provencher S,
Garcia G, Parent F, Hervé P, Simonneau G. Long-term response to
calcium channel blockers in idiopathic pulmonary arterial hyperten-
sion. Circulation 2005;111(23):3105–3111.
247. Simhan HN, Caritis SN. Prevention of preterm delivery. N Engl J
Med 2007;357(5):477–487.
248. Kiely DG, Elliot CA, Wilson VJ, Stewart P. Pregnancy and pulmo-
nary hypertension: new approaches to the management of a life
threatening condition. In: Steer PH, Gatzoulis MA, Baker P, eds.
Heart disease and pregnancy. London: RCOG Press, 2006:211–229.
249. Jonas MM, Tanser SJ. Lithium dilution measurement of cardiac output
and arterial pulse waveform analysis: an indicator dilution calibrated
beat-by-beat system for continuous estimation of cardiac output. Curr
Opin Crit Care 2002;8(3):257–261.
250. Kiely DG, Condliffe R, Wilson VJ, Gandhi SV, Elliot CA. Pregnancy
and pulmonary hypertension: a practical approach to management.
Obstetr Med 2013;6(4):144–154.
Pulmonary Circulation Volume 5 Number 3 September 2015 | 465
